# EDGAR Filing Document

**Accession Number:** 0000057725
**File Stem:** 0001558370-23-000786
**Filing Date:** 2023-2
**Character Count:** 217740
**Document Hash:** 403e41b484dcc6040f684a785fe14fbb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-000786.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001558370-23-000786

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 97

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LANNETT CO INC
- **CENTRAL INDEX KEY:** 0000057725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 230787699
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31298
- **FILM NUMBER:** 23581093

**BUSINESS ADDRESS:**
- **STREET 1:** 9000 STATE RD
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19136
- **BUSINESS PHONE:** 2153339000

**MAIL ADDRESS:**
- **STREET 1:** 9000 STATE ROAD
- **STREET 2:** 9000 STATE ROAD
- **CITY:** PHLADELPHIA
- **STATE:** PA
- **ZIP:** 19136

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NETHERLANDS SECURITIES INC
- **DATE OF NAME CHANGE:** 19660629

?xml version='1.0' encoding='UTF-8'?

[**Table of Contents**](#TOC)

------

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934** 

**FOR THE QUARTERLY PERIOD ENDED December 31, 2022**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934**

**FOR THE TRANSITION PERIOD FROM TO** 

**Commission File No. 001-31298**

**LANNETT COMPANY, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

| | |
|:---|:---|
| **State of Delaware** | **23-0787699** |
| (State of Incorporation) | (I.R.S. Employer I.D. No.) |

---

**1150 Northbrook Drive, Suite 155**

**Trevose, PA 19053**

**(215) 333-9000**

(Address of principal executive offices and telephone number)

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value<br> LCI | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Non-accelerated filer ☒ | Smaller reporting company ☐ |
| Emerging growth company ☐ |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12B-12 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each class of the registrant's common stock, as of the latest practical date.

---

| | |
|:---|:---|
| **Class** | **Outstanding as of January 31, 2023** |
| Common stock, par value $0.001 per share  | 43066265 |

---

------

[**Table of Contents**](#TOC)

**Table of Contents**

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **Page No.** |
| [**PART I. FINANCIAL INFORMATION**](#PARTIFINANCIALINFORMATION_979793) | [**PART I. FINANCIAL INFORMATION**](#PARTIFINANCIALINFORMATION_979793) | [**PART I. FINANCIAL INFORMATION**](#PARTIFINANCIALINFORMATION_979793) |  |
|  | [**ITEM 1.**](#ITEM1FINANCIALSTATEMENTS_525580) | [**FINANCIAL STATEMENTS (UNAUDITED)**](#ITEM1FINANCIALSTATEMENTS_525580) |  |
|  |  | [Consolidated Balance Sheets as of December 31, 2022 and June 30, 2022](#CONSOLIDATEDBALANCESHEETS_555105) | 3 |
|  |  | [Consolidated Statements of Operations for the three and six months ended December 31, 2022 and 2021](#CONSOLIDATEDSTATEMENTSOFOPERATIONS_47785) | 4 |
|  |  | [Consolidated Statements of Comprehensive Loss for the three and six months ended December 31, 2022 and 2021](#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINC) | 5 |
|  |  | [Consolidated Statements of Changes in Stockholders' Deficit for the three and six months ended December 31, 2022 and 2021](#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI)  | 6 |
|  |  | [Consolidated Statements of Cash Flows for the three and six months ended December 31, 2022 and 2021](#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_621452) | 7 |
|  |  | [Notes to Consolidated Financial Statements](#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_3) | 8 |
|  | [**ITEM 2.**](#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF) | [**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**](#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF) | 36 |
|  | [**ITEM 3**.](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR) | [**QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR) | 48 |
|  | [**ITEM 4**.](#ITEM4CONTROLSANDPROCEDURES_146376) | [**CONTROLS AND PROCEDURES**](#ITEM4CONTROLSANDPROCEDURES_146376) | 48 |
| [**PART II. OTHER INFORMATION**](#PARTIIOTHERINFORMATION_217087) | [**PART II. OTHER INFORMATION**](#PARTIIOTHERINFORMATION_217087) | [**PART II. OTHER INFORMATION**](#PARTIIOTHERINFORMATION_217087) |  |
|  | [**ITEM 1.**](#ITEM1LEGALPROCEEDINGS_652718) | [**LEGAL PROCEEDINGS**](#ITEM1LEGALPROCEEDINGS_652718) | 49 |
|  | [**ITEM 1A.**](#ITEM1ARISKFACTORS) | [**RISK FACTORS**](#ITEM1ARISKFACTORS) | 49 |
|  | [**ITEM 6.**](#ITEM6EXHIBITS_807381) | [**EXHIBITS**](#ITEM6EXHIBITS_807381) | 50 |

---

[**Table of Contents**](#TOC)

**PART I. FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**LANNETT COMPANY, INC.**

**CONSOLIDATED BALANCE SHEETS**

**(UNAUDITED)**

**(**In thousands, except share and per share data)

---

| | | |
|:---|:---|:---|
|  | **December 31, 2022** | **June 30, 2022** |
| **ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents  | $**55850** | $87854 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net  | **80344** | 56241 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | **94776** | 95158 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current income taxes receivable | **—** | 36793 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assets held for sale | **1300** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets  | **18257** | 14070 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets  | **250527** | 290116 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Property, plant and equipment, net**  | **116473** | 133178 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Intangible assets, net**  | **29639** | 32179 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Operating lease right-of-use assets** | **9274** | 9646 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Income taxes receivable** | **17984** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other assets**  | **14462** | 19316 |
| **TOTAL ASSETS** | $**438359** | $484435 |
| **LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable  | $**33165** | $29737 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses  | **25688** | 23667 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and payroll-related expenses  | **9151** | 8342 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rebates payable  | **21377** | 21568 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties payable | **7466** | 5677 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring liability | **410** | 490 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current operating lease liabilities | **2074** | 2064 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | **12885** | 13395 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities  | **112216** | 104940 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Long-term debt, net** | **623855** | 614948 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Long-term operating lease liabilities** | **9441** | 9994 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other liabilities** | **5121** | 5616 |
| **TOTAL LIABILITIES** | **750633** | 735498 |
| Commitments and contingencies (Notes 11 and 12) |  |  |
| **STOCKHOLDERS' DEFICIT** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Common stock** ($0.001 par value, 100,000,000 shares authorized; 42,996,851 and 42,269,137 shares issued; 41,247,806 and 40,704,572 shares outstanding at December 31, 2022 and June 30, 2022, respectively) | **43** | 42 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Additional paid-in capital**  | **367134** | 363957 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Accumulated deficit** | **(660713)** | (596386) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Accumulated other comprehensive loss**  | **(367)** | (411) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Treasury stock** (1,749,045 and 1,564,565 shares at December 31, 2022 and June 30, 2022, respectively) | **(18371)** | (18265) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' deficit** | **(312274)** | (251063) |
| **TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT** | $**438359** | $484435 |

---

The accompanying notes are an integral part of the Consolidated Financial Statements**.**

[**Table of Contents**](#TOC)

**LANNETT COMPANY, INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

(In thousands, except share and per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**  | **Three Months Ended**  | **Six Months Ended**  | **Six Months Ended**  |
|  | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** | **2022** | **2021** |
| **Net sales**  | $**80894** | $86508 | $**155973** | $188033 |
| **Cost of sales**  | **65258** | 76990 | **126543** | 157998 |
| **Amortization of intangibles** | **1358** | 3808 | **2553** | 7804 |
| **Gross profit**  | **14278** | 5710 | **26877** | 22231 |
| **Operating expenses (income):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses | **4928** | 4747 | **12107** | 10511 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | **18317** | 18791 | **35014** | 37696 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring expenses | **335** | 891 | **481** | 891 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset impairment charges | **5969** | 49361 | **10637** | 49361 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of intangible assets | **(500)** |  | **(3563)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses  | **29049** | 73790 | **54676** | 98459 |
| **Operating loss** | **(14771)** | (68080) | **(27799)** | (76228) |
| **Other income (expense), net:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment income | **399** | 46 | **491** | 80 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense  | **(15184)** | (14430) | **(30214)** | (28654) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on loan receivable | **(6826)** |  | **(6826)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income (expense) | **106** | 11 | **87** | (51) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expense, net | **(21505)** | (14373) | **(36462)** | (28625) |
| **Loss before income tax** | **(36276)** | (82453) | **(64261)** | (104853) |
| **Income tax expense (benefit)** | **32** | (1368) | **66** | (1426) |
| **Net loss** | $**(36308)** | $(81085) | $**(64327)** | $(103427) |
| **Loss per common share (1):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic  | $**(0.88)** | $(2.01) | $**(1.57)** | $(2.58) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**(0.88)** | $(2.01) | $**(1.57)** | $(2.58) |
| **Weighted average common shares outstanding (1):**  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic  | **41170839** | 40358127 | **41056607** | 40142974 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | **41170839** | 40358127 | **41056607** | 40142974 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) See Note 14 "Loss Per Common Share" for details on calculation.

The accompanying notes are an integral part of the Consolidated Financial Statements**.**

[**Table of Contents**](#TOC)

**LANNETT COMPANY, INC.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

**(UNAUDITED)**

(In thousands)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**  | **Three Months Ended**  | **Six Months Ended**  | **Six Months Ended**  |
|  | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** | **2022** | **2021** |
| **Net loss** | $**(36308)** | $(81085) | $**(64327)** | $(103427) |
| **Other comprehensive income:**  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation gain | **34** | 5 | **44** | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income | **34** | 5 | **44** | 29 |
| **Comprehensive loss** | $**(36274)** | $(81080) | $**(64283)** | $(103398) |

---

The accompanying notes are an integral part of the Consolidated Financial Statements**.**

[**Table of Contents**](#TOC)

**LANNETT COMPANY, INC.**

**CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT**

**(UNAUDITED)**

(In thousands)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** |
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares**<br>**Issued** | <br>**Amount** | <br>**Additional**<br>**Paid-In**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Loss** | <br>**Treasury**<br>**Stock** | <br>**Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance, September 30, 2022** | 42918 | $43 | $365573 | $(624405) | $(401) | $(18371) | $(277561) |
| Shares issued in connection with share-based compensation plans | 79 |  | 29 |  |  |  | 29 |
| Share-based compensation |  |  | 1532 |  |  |  | 1532 |
| Other comprehensive income |  |  |  |  | 34 |  | 34 |
| Net loss |  |  |  | (36308) |  |  | (36308) |
| **Balance, December 31, 2022** | **42997** | $**43** | $**367134** | $**(660713)** | $**(367)** | $**(18371)** | $**(312274)** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** |
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares**<br>**Issued** | <br>**Amount** | <br>**Additional**<br>**Paid-In**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Loss** | <br>**Treasury**<br>**Stock** | <br>**Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance, September 30, 2021** | 41787 | $42 | $358361 | $(387108) | $(524) | $(18124) | $(47353) |
| Shares issued in connection with share-based compensation plans | 266 |  | 95 |  |  |  | 95 |
| Share-based compensation |  |  | 2309 |  |  |  | 2309 |
| Purchase of treasury stock |  |  |  |  |  | (131) | (131) |
| Other comprehensive income |  |  |  |  | 5 |  | 5 |
| Net loss |  |  |  | (81085) |  |  | (81085) |
| **Balance, December 31, 2021** | **42053** | $**42** | $**360765** | $**(468193)** | $**(519)** | $**(18255)** | $**(126160)** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** |
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares**<br>**Issued** | <br>**Amount** | <br>**Additional**<br>**Paid-In**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Loss** | <br>**Treasury**<br>**Stock** | <br>**Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance, June 30, 2022** | 42269 | $42 | $363957 | $(596386) | $(411) | $(18265) | $(251063) |
| Shares issued in connection with share-based compensation plans | 728 | 1 | 66 |  |  |  | 67 |
| Share-based compensation |  |  | 3111 |  |  |  | 3111 |
| Purchase of treasury stock |  |  |  |  |  | (106) | (106) |
| Other comprehensive income |  |  |  |  | 44 |  | 44 |
| Net loss |  |  |  | (64327) |  |  | (64327) |
| **Balance, December 31, 2022** | **42997** | $**43** | $**367134** | $**(660713)** | $**(367)** | $**(18371)** | $**(312274)** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** |
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares**<br>**Issued** | <br>**Amount** | <br>**Additional**<br>**Paid-In**<br>**Capital** | <br>**Retained**<br>**Earnings** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Loss** | <br>**Treasury**<br>**Stock** | <br>**Total**<br>**Stockholders'**<br>**Equity** |
| **Balance, June 30, 2021** | 40913 | $41 | $355239 | $(364766) | $(548) | $(17437) | $(27471) |
| Shares issued in connection with share-based compensation plans | 1140 | 1 | 199 |  |  |  | 200 |
| Share-based compensation |  |  | 5327 |  |  |  | 5327 |
| Purchase of treasury stock |  |  |  |  |  | (818) | (818) |
| Other comprehensive income |  |  |  |  | 29 |  | 29 |
| Net loss |  |  |  | (103427) |  |  | (103427) |
| **Balance, December 31, 2021** | **42053** | $**42** | $**360765** | $**(468193)** | $**(519)** | $**(18255)** | $**(126160)** |

---

The accompanying notes are an integral part of the Consolidated Financial Statements**.**

[**Table of Contents**](#TOC)

**LANNETT COMPANY, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

(In thousands)

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended**  | **Six Months Ended**  |
|  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** |
| **OPERATING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | $**(64327)** | $(103427) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Adjustments to reconcile net loss to net cash (used in) provided by operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization  | **12501** | 18871 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation  | **3111** | 5327 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset impairment charges | **10637** | 49361 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on loan receivable | **6826** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on sale/disposal of assets | **(3563)** | 51 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrual of payment-in-kind interest on Second Lien Credit Facility | **5453** | 10024 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount and other debt issuance costs | **3635** | 2959 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for inventory write-downs | **3259** | 4054 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other noncash expenses | **453** | 393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Changes in assets and liabilities which provided (used) cash:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | **(24103)** | 32559 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories  | **(2877)** | (288) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes receivable/payable | **18866** | (833) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | **(6340)** | (2255) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rebates payable  | **(191)** | 6180 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties payable | **1789** | (3092) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring liability | **(80)** | 612 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease assets/liabilities | **(624)** | (561) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable  | **3428** | (3597) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses  | **1871** | (1871) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and payroll-related expenses | **809** | (1074) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | **(1062)** | 450 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by operating activities  | **(30529)** | 13843 |
| **INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment  | **(5180)** | (6758) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of assets | **4700** | 353 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of intangible assets | **(1000)** | (1500) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | **(1480)** | (7905) |
| **FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of stock | **67** | 200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of treasury stock | **(106)** | (818) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | **(39)** | (618) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect on cash and cash equivalents of changes in foreign exchange rates | **44** | 29 |
| **NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH** | **(32004)** | 5349 |
| **CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD** | **92854** | 98286 |
| **CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD** | $**60850** | $103635 |
| **SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest paid | $**21185** | $15131 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes refunded | $**(18798)** | $(592) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment included in accounts payable | $**440** | $999 |

---

The accompanying notes are an integral part of the Consolidated Financial Statements**.**

[**Table of Contents**](#TOC)

**LANNETT COMPANY, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

**Note 1. Interim Financial Information**

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for the presentation of interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited financial statements do not include all the information and footnotes necessary for a comprehensive presentation of the financial position, results of operations and cash flows for the periods presented. In the opinion of management, the unaudited financial statements include all the normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the three and six months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2023. These unaudited financial statements should be read in combination with the other Notes in this section; "Management's Discussion and Analysis of Financial Condition and Results of Operations" appearing in Item 2; and the Consolidated Financial Statements, including the Notes to the Consolidated Financial Statements, included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022. The Consolidated Balance Sheet as of June 30, 2022 was derived from audited financial statements.

**Note 2. The Business and Nature of Operations**

Lannett Company, Inc. (a Delaware corporation) and its subsidiaries (collectively, the "Company" or "Lannett") primarily develop, manufacture, package, market and distribute solid oral and extended release (tablets and capsules), topical, nasal and oral solution finished dosage forms of drugs that address a wide range of therapeutic areas. Certain of these products are manufactured by others and distributed by the Company.

The Company operates a pharmaceutical manufacturing plant in Seymour, Indiana. During Fiscal 2022, the Company completed the sale of its Silarx Pharmaceuticals, Inc. ("Silarx") facility in Carmel, New York. In connection with the sale, the buyer will continue to produce certain products on behalf of the Company at the Carmel facility while the Company completes the transfer of such products to its Seymour, Indiana plant.

The Company's customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations.

[**Table of Contents**](#TOC)

*NYSE Notices of Failure to Satisfy a Continued Listing Rule or Standard*

On March 2, 2022, we received notice from the New York Stock Exchange (the "NYSE") that we were no longer in compliance with the NYSE continued listing standards, set forth in Section 802.01B of the NYSE's Listed Company Manual, because the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50.0 million and, at the same time, our shareholders' equity was less than $50.0 million. If the Company's average global market capitalization over a consecutive 30 trading-day period drops below $15.0 million, the NYSE will initiate delisting proceedings. As of January 31, 2023, the 30 trading-day average global market capitalization of the Company was approximately $26.4 million, and the Company's absolute market capitalization was approximately $23.7 million. In accordance with the NYSE listing requirements, we submitted a plan that demonstrates how we expect to return to compliance with Section 802.01B within 18 months. On May 26, 2022, the Company received notice from the NYSE that the plan was accepted. The NYSE has been performing quarterly reviews during the 18 months from the Company's receipt of the notice for compliance with the goals and initiatives as outlined in the Company's plan. Failure to satisfy the requisite goals or initiatives may result in the Company being subject to NYSE trading suspension at that time. The Company is required to achieve the minimum continued listing standards of either average global market capitalization over a consecutive 30 trading-day period of $50 million or total stockholders' equity of $50 million at the completion of the 18-month plan period, and failure to achieve any of the minimum requirements at the end of the 18-month period may result in the Company being suspended by the NYSE, which may make an application to the SEC to delist the Company's common stock. There can be no assurances that the Company will maintain compliance with the plan.

In addition, on March 14, 2022, the Company received a second notice from the NYSE that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE's Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 per share over a consecutive 30 trading-day period. In order to regain compliance, on the last trading day of any calendar month during the cure period or on the last business day of the six-month cure period, the Company's shares of common stock must demonstrate (i) a closing price of at least $1.00 per share and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on such date. On January 25, 2023, the stockholders of the Company and the Board of Directors approved a 1-for-4 reverse stock split, and the Company plans to file an amendment to our Certificate of Incorporation to effectuate the reverse stock split on February 6, 2023. The Company's common stock will begin trading on a split-adjusted basis on February 7, 2023. If the Company's stock price exceeds $1.00 on a split-adjusted basis for at least 30 trading days following the reverse stock split, the price condition will be deemed cured. However, there can be no assurances that the Company will meet this continued listing standard within the specified cure period.

If we are unable to satisfy the NYSE criteria for continued listing, our common stock would be subject to delisting. A delisting of our common stock could negatively impact our reputation and, consequently, our business by, among other things, reducing the liquidity and market price of our common stock; reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise equity financing; decreasing the amount of news and analyst coverage of the Company; and limiting our ability to issue additional securities or obtain additional financing in the future. In addition, if the Company ceases to be listed or quoted on any of The NYSE, The Nasdaq Global Select Market or The Nasdaq Global Market (or any of their respective successors), holders of the outstanding 4.50% Convertible Senior Notes (the "Convertible Notes") will have the option to require the Company to repurchase for cash all of such holder's notes at 100% of the principal amount, plus accrued and unpaid interest. An acceleration of our debt maturities would put significant pressure on our liquidity and ability to continue to operate as a going concern; however, in the event of a delisting or likely delisting, the Company intends to work proactively and collaboratively with its debt holders to amend its credit documents and indentures or pursue other alternative plans that are probable of execution in order to avoid a default and acceleration of the Company's indebtedness.

[**Table of Contents**](#TOC)

**Note 3. Summary of Significant Accounting Policies**

***Basis of Presentation***

The Consolidated Financial Statements have been prepared in conformity with U.S. GAAP.

***Principles of consolidation***

The Consolidated Financial Statements include the accounts of Lannett Company, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.

***Reclassifications***

Certain prior year amounts have been reclassified to conform to the current year financial statement presentation.

***Use of estimates***

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition and sales deductions for estimated chargebacks, rebates, returns and other adjustments including a provision for the Company's liability under the Medicare Part D program. Additionally, significant estimates and assumptions are required when determining the value of inventories and long-lived assets, including intangible assets, income taxes, and contingencies.

Because of the inherent subjectivity and complexity involved in these estimates and assumptions, actual results could differ from those estimates.

***Foreign currency translation***

The Consolidated Financial Statements are presented in U.S. dollars, the reporting currency of the Company. The financial statements of the Company's foreign subsidiary are maintained in local currency and translated into U.S. dollars at the end of each reporting period. Assets and liabilities are translated at period-end exchange rates, while revenues and expenses are translated at average exchange rates during the period. The adjustments resulting from the use of differing exchange rates are recorded as part of stockholders' equity (deficit) in accumulated other comprehensive income (loss). Gains and losses resulting from transactions denominated in foreign currencies are recognized in the Consolidated Statements of Operations under other income (loss). Amounts recorded due to foreign currency fluctuations are immaterial to the Consolidated Financial Statements.

***Cash, cash equivalents and restricted cash***

The Company considers all highly liquid investments with original maturities less than or equal to three months at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value, and consist of bank deposits and money market funds. The Company maintains its cash deposits and cash equivalents at well-known, stable financial institutions. Such amounts frequently exceed insured limits. In connection with the Second Lien Secured Loan Facility ("Second Lien Facility"), the Company is required to maintain at least $5.0 million in a deposit account at all times, subject to control by the Second Lien Collateral Agent. At December 31, 2022, the Company classified this balance as restricted cash, which is included in other assets on the Consolidated Balance Sheets.

[**Table of Contents**](#TOC)

Presented in the table below is a reconciliation of the cash, cash equivalents and restricted cash amounts presented on the Consolidated Balance Sheets to the sum of such amounts presented on the Consolidated Statements of Cash Flows for the periods ended December 31, 2022 and 2021.

---

| | | |
|:---|:---|:---|
|  | **December 31, 2022** | **December 31, 2021** |
| Cash and cash equivalents | $55850 | $98635 |
| Restricted cash, included in other assets  | 5000 | 5000 |
| Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows | $60850 | $103635 |

---

***Allowance for expected credit losses***

The Company complies with ASU 2016-13, *Measurement of Credit Losses on Financial Instruments*, which requires the Company to recognize an allowance that reflects a current estimate of credit losses expected to be incurred over the life of the financial asset, including trade receivables. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for expected credit losses by considering a number of factors, including the length of time balances are past due, the Company's previous loss history, the customer's current ability to pay its obligations to the Company and the expected condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible.

***Inventories***

Inventories are stated at the lower of cost or net realizable value by the first-in, first-out method. Inventories are regularly reviewed and write-downs for excess and obsolete inventory are recorded based primarily on current inventory levels, expiration date and estimated sales forecasts.

***Property, Plant and Equipment***

Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed on a straight-line basis over the assets' estimated useful lives. Repairs and maintenance costs that do not extend the useful life of the asset are expensed as incurred.

***Intangible Assets***

Definite-lived intangible assets are stated at cost less accumulated amortization. Amortization of definite-lived intangible assets is computed on a straight-line basis over the assets' estimated useful lives, which commence upon first shipment of the product associated with the intangible asset. The Company continually evaluates the reasonableness of the useful lives of these assets. Costs to renew or extend the term of a recognized intangible asset are expensed as incurred.

***Valuation of Long-Lived Assets, including Intangible Assets***

The Company's long-lived assets primarily consist of property, plant and equipment and definite-lived intangible assets. Property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances ("triggering events") indicate that the carrying amount of the asset may not be recoverable. If a triggering event is determined to have occurred, the asset's carrying value is compared to the future undiscounted cash flows expected to be generated by the asset. If the carrying value exceeds the undiscounted cash flows of the asset, then impairment exists.

An impairment loss is measured as the excess of the asset's carrying value over its fair value, which in most cases is calculated using a discounted cash flow model. Discounted cash flow models are highly reliant on various assumptions which are considered Level 3 inputs, including estimates of future cash flows (including long-term growth rates), discount rates and the probability of achieving the estimated cash flows.

[**Table of Contents**](#TOC)

***Revenue Disaggregation***

The Company operates in one reportable segment, generic pharmaceuticals. As such, the Company aggregates its financial information for all products. The following table identifies the Company's net sales by medical indication for the three and six months ended December 31, 2022 and 2021.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended**  | **Three Months Ended**  | **Six Months Ended**  | **Six Months Ended**  |
| | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
| <br>**(In thousands)**<br>**Medical Indication** | **2022** | **2021** | **2022** | **2021** |
| Analgesic | $2592 | $3919 | $6016 | $9233 |
| Anti-Psychosis | 2575 | 2095 | 5195 | 5810 |
| Cardiovascular  | 13089 | 9753 | 23971 | 23853 |
| Central Nervous System | 21782 | 22340 | 42576 | 45125 |
| Endocrinology | 5831 | 8297 | 13143 | 16142 |
| Gastrointestinal | 8716 | 14023 | 16658 | 29263 |
| Infectious Disease | 4989 | 6520 | 10058 | 19035 |
| Migraine | 3574 | 4446 | 6898 | 9131 |
| Respiratory/Allergy/Cough/Cold | 1468 | 1868 | 2670 | 4982 |
| Other | 10955 | 10275 | 19714 | 20627 |
| Contract manufacturing revenue | 5323 | 2972 | 9074 | 4832 |
| Total net sales | $80894 | $86508 | $155973 | $188033 |

---

***Customer, Supplier and Product Concentration***

For the three and six months ended December 31, 2022 and 2021, the Company did not have any products that accounted for at least 10% of total net sales. Products are defined as containing the same active ingredient or combination of ingredients.

The following table presents the percentage of total net sales, for the three and six months ended December 31, 2022 and 2021, for certain of the Company's customers which accounted for at least 10% of total net sales in any of those periods:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**  | **Three Months Ended**  | **Six Months Ended**  | **Six Months Ended**  |
|  | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** | **2022** | **2021** |
| Customer A | 22% | 26% | 22% | 28% |
| Customer B | 21% | 15% | 21% | 17% |
| Customer C | 16% | 14% | 16% | 14% |

---

***Revenue Recognition***

Under Accounting Standards Codification ("ASC") Topic 606, *Revenue from Contracts with Customers*, the Company recognizes revenue when (or as) we satisfy our performance obligations by transferring a promised good or service to a customer at an amount that reflects the consideration the Company is expected to be entitled. Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship product to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. Under ASC 606, *Revenue from Contracts with* Customers, the Company recognizes certain contract manufacturing arrangements "over time."

When revenue is recognized, a simultaneous adjustment to gross sales is made for estimated chargebacks, rebates, returns, promotional adjustments and other potential adjustments. These provisions are primarily estimated based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers and other factors known to management at the time of accrual. Accruals for provisions are presented in the Consolidated Financial

[**Table of Contents**](#TOC)

Statements as a reduction to gross sales with the corresponding reserve presented as a reduction of accounts receivable or included as rebates payable, depending on the nature of the reserve.

Provisions for chargebacks, rebates, returns and other adjustments require varying degrees of subjectivity. While rebates generally are based on contractual terms and require minimal estimation, chargebacks and returns require management to make more subjective assumptions. Each major category is discussed in detail below:

***Chargebacks***

The provision for chargebacks is the most significant and complex estimate used in the recognition of revenue. The Company sells its products directly to wholesale distributors, generic distributors, retail pharmacy chains and mail-order pharmacies. The Company also sells its products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes and group purchasing organizations, collectively referred to as "indirect customers." The Company enters into agreements with its indirect customers to establish pricing for certain products. The indirect customers then independently select a wholesaler from which to purchase the products. If the price paid by the indirect customers is lower than the price paid by the wholesaler, the Company will provide a credit, called a chargeback, to the wholesaler for the difference between the contractual price with the indirect customers and the wholesaler purchase price. The provision for chargebacks is based on expected sell-through levels by the Company's wholesale customers to the indirect customers and estimated wholesaler inventory levels. As sales to the large wholesale customers, such as Cardinal Health, AmerisourceBergen and McKesson increase (decrease), the reserve for chargebacks will also generally increase (decrease). However, the size of the increase (decrease) depends on product mix and the amount of sales made to indirect customers with which the Company has specific chargeback agreements. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve.

***Rebates***

Rebates are offered to the Company's key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. Additionally, as a result of the Patient Protection and Affordable Care Act ("PPACA") enacted in the U.S. in March 2010, the Company participates in a cost-sharing program for certain Medicare Part D beneficiaries designed primarily for the sale of brand drugs and certain generic drugs if their Food and Drug Administration ("FDA") approval was granted under a New Drug Application ("NDA") or 505(b) NDA versus an Abbreviated New Drug application ("ANDA"). Drugs purchased within the Medicare Part D coverage gap (commonly referred to as the "donut hole") result in additional rebates. The Company estimates the reserve for rebates and other promotional credit programs based on the specific terms in each agreement when revenue is recognized. The reserve for rebates increases (decreases) as sales to certain wholesale and retail customers increase (decrease). However, since these rebate programs are not identical for all customers, the size of the reserve will depend on the mix of sales to customers that are eligible to receive rebates.

***Returns***

Consistent with industry practice, the Company has a product returns policy that allows customers to return product within a specified time period prior to and subsequent to the product's expiration date in exchange for a credit to be applied to future purchases. The Company's policy requires that the customer obtain pre-approval from the Company for any qualifying return. The Company estimates its provision for returns based on historical experience, changes to business practices, credit terms and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Generally, the reserve for returns increases as net sales increase.

[**Table of Contents**](#TOC)

***Other Adjustments***

Other adjustments consist primarily of "price adjustments," also known as "shelf-stock adjustments" and "price protections," which are both credits issued to reflect increases or decreases in the invoice or contract prices of the Company's products. In the case of a price decrease, a credit is given for product remaining in customer's inventories at the time of the price reduction. Contractual price protection results in a similar credit when the invoice or contract prices of the Company's products increase, effectively allowing customers to purchase products at previous prices for a specified period of time. Amounts recorded for estimated shelf-stock adjustments and price protections are based upon specified terms with direct customers, estimated changes in market prices and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available. Other adjustments also include prompt payment discounts and "failure-to-supply" adjustments. If the Company is unable to fulfill certain customer orders, the customer can purchase products from our competitors at their prices and charge the Company for any difference in our contractually agreed upon prices.

***Leases***

Under ASC Topic 842, *Leases*, when the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. Once a lease has been identified, the Company must determine the lease term, the present value of lease payments and the classification of the lease as either operating or financing.

The lease term is determined to be the non-cancelable period including any lessee renewal options which are considered to be reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The present value of lease payments includes fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. To calculate the present value of lease payments, we use our incremental borrowing rate based on the information available at commencement date, as the rate implicit in the lease is generally not readily available.

In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors.

Upon the commencement of the lease, the Company will record a lease liability and right-of-use ("ROU") asset based on the present value of the future minimum lease payments over the lease term at commencement date. The ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred.

For operating leases, a single lease cost is generally recognized in the Consolidated Statements of Operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. For finance leases, amortization expense and interest expense are recognized separately in the Consolidated Statements of Operations, with amortization expense generally recorded on a straight-line basis and interest expense recorded using the effective interest method. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred. The Company does not recognize short-term leases of 12 months or less on its Consolidated Balance Sheets.

[**Table of Contents**](#TOC)

***Cost of Sales, including Amortization of Intangibles***

Cost of sales includes all costs related to bringing products to their final selling destination, which includes direct and indirect costs, such as direct material, labor and overhead expenses. Additionally, cost of sales includes product royalties, depreciation, amortization and costs to renew or extend recognized intangible assets, freight charges and other shipping and handling expenses.

***Research and Development***

Research and development costs are expensed as incurred, including all production costs until a drug candidate is approved by the FDA. Research and development expenses include costs associated with internal projects as well as costs associated with third-party research and development contracts.

***Contingencies***

Loss contingencies, including litigation-related contingencies, are included in the Consolidated Statements of Operations when the Company concludes that a loss is both probable and reasonably estimable. Legal fees for litigation-related matters are expensed as incurred and included in the Consolidated Statements of Operations under the Selling, general and administrative expenses line item.

***Restructuring Costs***

The Company records charges associated with approved restructuring plans to remove duplicative headcount and infrastructure associated with business acquisitions or to simplify business processes. Restructuring charges can include severance costs to eliminate a specified number of employees, infrastructure charges to vacate facilities and consolidate operations and contract cancellation costs. The Company records restructuring charges based on estimated employee terminations, site closure and consolidation plans. The Company accrues severance and other employee separation costs under these actions when it is probable that a liability exists, and the amount is reasonably estimable.

***Share-Based Compensation***

Share-based compensation costs are recognized over the requisite service period, typically the vesting period, using a straight-line method, based on the fair value of the instrument on the date of grant less an estimate for expected forfeitures. The Company uses the stock price on the grant date to value restricted stock and performance-based shares with vesting based on the satisfaction of a performance condition. The Company uses the Black-Scholes valuation model to determine the fair value of stock options and the Monte-Carlo simulation model to determine the fair value of performance-based shares with a market condition. The Black-Scholes valuation and Monte-Carlo simulation models include various assumptions, including the expected volatility, the expected life of the award, dividend yield and the risk-free interest rate as well as performance assumptions of peer companies. These assumptions involve inherent uncertainties based on market conditions which are generally outside the Company's control. Changes in these assumptions could have a material impact on share-based compensation costs recognized in the Consolidated Financial Statements.

***Self-Insurance***

The Company self-insures for certain employee medical and prescription benefits. The Company also maintains stop loss coverage with third party insurers to limit its total liability exposure. The liability for self-insured risks is primarily calculated using independent third-party actuarial valuations which take into account actual claims, claims growth and claims incurred but not yet reported. Actual experience, including claim frequency and severity as well as health-care inflation, could result in different liabilities than the amounts currently recorded. The liability for self-insured risks under this plan was $1.0 million and $0.5 million as of December 31, 2022 and June 30, 2022, respectively, and is recorded in the accrued payroll and payroll-related expenses caption in the Consolidated Balance Sheets.

[**Table of Contents**](#TOC)

***Income Taxes***

The Company uses the liability method to account for income taxes as prescribed by ASC 740, *Income Taxes*. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense (benefit) is the result of changes in deferred tax assets and liabilities. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates in the period during which they are signed into law. The Company evaluates the need for a valuation allowance each reporting period weighing all positive and negative evidence. The factors used to assess the likelihood of realization include, but are not limited to, the Company's forecast of future taxable income, historical results of operations, statutory expirations and available tax planning strategies and actions that could be implemented to realize the net deferred tax assets. Under ASC 740, *Income Taxes*, a valuation allowance is required when it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The Company may recognize the tax benefit from an uncertain tax position claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The authoritative accounting standards also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

***Earnings (Loss) Per Common Share***

The presentation of basic and diluted earnings (loss) per common share is required on the face of the Company's Consolidated Statements of Operations as well as a reconciliation of the computation of basic earnings (loss) per common share to diluted earnings (loss) per common share. In accordance with ASC 260, *Earnings per share*, the Company computes earnings (loss) per share using the two-class method, which requires an allocation of earnings between the holders of common stock and the Company's participating security holders. The warrants issued in connection with the Second Lien Secured Loan Facility (the "Warrants") are considered participating securities, as discussed further in Note 13 "Warrants." Basic earnings (loss) per share is calculated by dividing net income (loss) available to common stockholders, which excludes the income allocated to participating security holders, by the basic weighted average common shares outstanding.

For purposes of determining diluted earnings per share, the Company further adjusts the basic earnings per share to include the effect of potentially dilutive shares outstanding, including options and restricted stock awards, the 4.50% Convertible Senior Notes (the "Convertible Notes"), and the Warrants. In this calculation, the Company reallocates net income based on the rights of each potentially dilutive share and will report the most dilutive earnings (loss) per share. The weighted average number of diluted shares is adjusted for the potential dilutive effect of the exercise of stock options, treats unvested restricted stock as if it were vested, includes performance-based shares that would be issued if the performance criteria were met as of the end of the reporting period, and assumes the conversion of the Convertible Notes. The Company uses the "if-converted" method to compute earnings (loss) per share when assuming the conversion of the Convertible Notes, which is calculated by dividing the adjusted "if-converted" net income by the adjusted weighted average number of shares of common stock outstanding during the period. The adjusted "if-converted" net income is adjusted for interest expense and amortization of debt issuance costs, both net of tax, associated with the Convertible Notes. Because the Warrants do not participate in losses, the Company will allocate undistributed earnings when calculating basic and diluted earnings per share in periods of net income only. Anti-dilutive securities are excluded from the calculation. Dilutive shares are also excluded in the calculation in periods of net loss because the effect of including such securities would be anti-dilutive.

[**Table of Contents**](#TOC)

***Comprehensive Income (Loss)***

Comprehensive income (loss) reflects all changes in equity during a period except those that resulted from investments by or distributions to the Company's stockholders. This includes, but is not limited to, foreign currency translation gain (loss). Other comprehensive income (loss) refers to gains and losses that are included in comprehensive income (loss) but excluded from income (loss) for all amounts are recorded directly as an adjustment to stockholders' equity.

**Note 4. Restructuring Charges**

On December 15, 2022, the Company authorized a restructuring and cost savings plan (the "2022 Restructuring Plan") to streamline and realign our operations to ensure the continued progression of our existing pipeline and future growth. The 2022 Restructuring Plan includes operational improvements and cost efficiencies as well as engagement with more external partners and technology providers, globally, to execute on our R&D plans and operations.

The total reduction in headcount, and the basis of the estimated severance costs, for the 2022 Restructuring Plan is expected to be approximately 60 positions. The Company expects the reduction in force to be completed by the end of Fiscal 2023. The Company estimates that it will incur approximately $3 million in severance-related costs in connection with the 2022 Restructuring Plan. A reconciliation of the changes in restructuring liabilities associated with the 2022 Restructuring Plan from June 30, 2022 through December 2022 is set forth in the following table:

---

| | |
|:---|:---|
| <br>**(In thousands)** | **Employee**<br>**Separation Costs** |
| Balance at June 30, 2022 | $— |
| Restructuring charges | 317 |
| Payments |  |
| Balance at December 31, 2022 | $317 |

---

In connection with the shift in our R&D operations, the Company also anticipates exiting our State Road and Torresdale facilities in Philadelphia, Pennsylvania by the end of our current fiscal year. In the first quarter of Fiscal 2023, the Company recorded an impairment charge of $4.7 million to adjust the State Road facility and certain equipment to fair value less costs to sell and the remaining assets of $1.3 million were recorded in the assets held for sale caption in the Consolidated Balance Sheet. In the second quarter of Fiscal 2023, the Company recorded an impairment charge of $6.0 million to adjust the Torresdale facility to its approximate fair value.

**Note 5. Accounts Receivable, net**

Accounts receivable, net consisted of the following components at December 31, 2022 and June 30, 2022:

---

| | | |
|:---|:---|:---|
| <br>**(In thousands)** | **December 31,** <br>**2022** | **June 30,** <br>**2022** |
| Gross accounts receivable  | $187187 | $199242 |
| Less: Chargebacks reserve  | (39739) | (54501) |
| Less: Rebates reserve  | (16139) | (26921) |
| Less: Returns reserve  | (37190) | (46478) |
| Less: Other deductions  | (12826) | (14117) |
| Less: Allowance for expected credit losses | (949) | (984) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net  | $80344 | $56241 |

---

For the three months ended December 31, 2022, the Company recorded a provision for chargebacks, rebates (including rebates presented as rebates payable), returns and other deductions of $94.7 million, $25.7 million, $8.2 million and $7.2 million, respectively. For the three months ended December 31, 2021, the Company recorded a provision for chargebacks, rebates (including rebates presented as rebates payable), returns and other deductions of $114.7 million, $26.5 million, $7.4 million and $7.8 million, respectively.

[**Table of Contents**](#TOC)

For the six months ended December 31, 2022, the Company recorded a provision for chargebacks, rebates (including rebates presented as rebates payable), returns and other deductions of $180.9 million, $47.3 million, $13.5 million and $13.9 million, respectively. For the six months ended December 31, 2021, the Company recorded a provision for chargebacks, rebates (including rebates presented as rebates payable), returns and other deductions of $245.9 million, $55.3 million, $13.3 million and $26.8 million, respectively.

The following table identifies the activity and ending balances of each major category of revenue-related reserve for the six months ended December 31, 2022 and 2021:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reserve Category**<br>**(In thousands)** | <br>**Chargebacks** | <br>**Rebates** | <br>**Returns** | <br>**Other** | <br>**Total** |
| Balance at June 30, 2022 | $54501 | $48489 | $46478 | $14117 | $163585 |
| Current period provision | 180856 | 47322 | 13546 | 13931 | 255655 |
| Credits issued during the period | (195618) | (58295) | (22834) | (15222) | (291969) |
| Balance at December 31, 2022 | $39739 | $37516 | $37190 | $12826 | $127271 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reserve Category**<br>**(In thousands)** | <br>**Chargebacks** | <br>**Rebates** | <br>**Returns** | <br>**Other** | <br>**Total** |
| Balance at June 30, 2021 | $69564 | $35297 | $38395 | $15505 | $158761 |
| Current period provision | 245900 | 55262 | 13305 | 26761 | 341228 |
| Credits issued during the period | (248631) | (46857) | (14930) | (26968) | (337386) |
| Balance at December 31, 2021 | $66833 | $43702 | $36770 | $15298 | $162603 |

---

For the three months ended December 31, 2022 and 2021, as a percentage of gross sales the provision for chargebacks was 44.8% and 47.8%, the provision for rebates was 12.2% and 11.1%, the provision for returns was 3.9% and 3.1% and the provision for other adjustments was 3.4% and 3.2%, respectively.

For the six months ended December 31, 2022 and 2021, as a percentage of gross sales the provision for chargebacks was 44.9% and 46.9%, the provision for rebates was 11.8% and 10.5%, the provision for returns was 3.4% and 2.5% and the provision for other adjustments was 3.5% and 5.1%, respectively.

The decrease in the reserve for chargebacks from June 30, 2022 to December 31, 2022 was primarily attributable to changes in product and customer sales mix. Additionally, the reserve for rebates and returns decreased during the first six months of Fiscal 2023 due to the timing of payments. Higher than average returns in prior periods also contributed to the decrease in the reserve for returns during the period.

**Note 6. Inventories**

Inventories at December 31, 2022 and June 30, 2022 consisted of the following:

---

| | | |
|:---|:---|:---|
| <br>**(In thousands)** | **December 31,** <br>**2022** | **June 30,** <br>**2022** |
| Raw Materials  | $40809 | $39297 |
| Work-in-process  | 10152 | 9313 |
| Finished Goods  | 43815 | 46548 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total  | $94776 | $95158 |

---

During the three months ended December 31, 2022 and 2021, the Company recorded write-downs to net realizable value for excess and obsolete inventory of $0.6 million and $1.2 million, respectively. During the six months ended December 31, 2022 and 2021, the Company recorded write-downs to net realizable value for excess and obsolete inventory of $3.3 million and $4.1 million, respectively

[**Table of Contents**](#TOC)

**Note 7. Property, Plant and Equipment, net**

Property, plant and equipment, net at December 31, 2022 and June 30, 2022 consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| <br>**(In thousands)** | <br>**Useful Lives** | **December 31,** <br>**2022** | **June 30,** <br>**2022** |
| Land  |  | $348 | $533 |
| Building and improvements  | 10 - 39 years | 77580 | 93701 |
| Machinery and equipment  | 5 - 10 years | 155598 | 158854 |
| Furniture and fixtures  | 5 - 7 years | 3088 | 3367 |
| Less accumulated depreciation  |  | (135883) | (136433) |
|  |  | 100731 | 120022 |
| Construction in progress  |  | 15742 | 13156 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, net  |  | $116473 | $133178 |

---

Depreciation expense for the three months ended December 31, 2022 and 2021 was $4.9 million and $5.5 million, respectively. Depreciation expense for the six months ended December 31, 2022 and 2021 was $9.9 million and $11.1 million, respectively.

In the second quarter of Fiscal 2023, the Company recorded an impairment charge of $6.0 million to adjust the Torresdale facility to its approximate fair value in connection with the 2022 Restructuring Plan. See Note 4 "Restructuring Charges" for additional information on the plan.

Property, plant and equipment, net included amounts held in foreign countries in the amount of $0.8 million and $0.7 million at December 31, 2022 and June 30, 2022, respectively.

**Note 8. Fair Value Measurements**

The Company's financial instruments recorded in the Consolidated Balance Sheets include cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt obligations. The Company's cash and cash equivalents include bank deposits and money market funds. The carrying value of certain financial instruments, primarily cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values based upon the short-term nature of their maturity dates.

The Company follows the authoritative guidance of ASC Topic 820, *Fair Value Measurements and Disclosures.* Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchy is defined as follows:

Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2 — Directly or indirectly observable inputs, other than quoted prices, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are material to the fair value of the asset or liability. Financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation are examples of Level 3 assets and liabilities.

[**Table of Contents**](#TOC)

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

*Financial Instruments Disclosed, But Not Reported, at Fair Value*

We estimate the fair value of 7.750% senior secured notes due 2026 (the "Notes") and the Convertible Notes using market quotations for debt that have quoted prices in active markets (Level 1). Since our Second Lien Facility does not trade on a daily basis in an active market, the fair value estimate is based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities (Level 2). The estimated fair value of the Notes as of December 31, 2022 and June 30, 2022 was approximately $79 million and $140 million, respectively. The estimated fair value of the Second Lien Facility as of December 31, 2022 and June 30, 2022 was approximately $43 million and $76 million, respectively. The decline in the fair value of the Notes and Second Lien Facility is primarily a reflection of the increased competitive pressures on the Company's recent financial performance, which, in part, resulted in a downgrade to the Company's credit rating. The estimated fair value of the Convertible Notes was approximately $13 million and $25 million as of December 31, 2022 and June 30, 2022, respectively. The fair value of the Convertible Notes as of December 31, 2022 was lower than the carrying value primarily due to the Company's stock price of $0.52 at December 31, 2022 as compared to the $15.29 conversion price as well as the Company's downgraded credit rating.

**Note 9. Intangible Assets**

Intangible assets, net as of December 31, 2022 and June 30, 2022 consisted of the following:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Gross Carrying Amount** | **Gross Carrying Amount** | **Accumulated Amortization** | **Accumulated Amortization** | **Intangible Assets, Net** | **Intangible Assets, Net** |
| <br>**(In thousands)** | **Weighted**<br>**Avg. Life** <br>**(Yrs.)** | **December 31,** <br>**2022** | **June 30,** <br>**2022** | **December 31,** <br>**2022** | **June 30,** <br>**2022** | **December 31,** <br>**2022** | **June 30,** <br>**2022** |
| Definite-lived: |  |  |  |  |  |  |  |
| KUPI trade name | 2 | $2920 | $2920 | $(2920) | $(2920) | $— | $— |
| KUPI other intangible assets | 15 | 19000 | 19000 | (8995) | (8362) | 10005 | 10638 |
| Silarx product rights | 15 | 18531 | 20000 | (6383) | (6222) | 12148 | 13778 |
| Other product rights | 7 | 17242 | 16242 | (9756) | (8479) | 7486 | 7763 |
| Total intangible assets, net |  | $57693 | $58162 | $(28054) | $(25983) | $29639 | $32179 |

---

For the three months ended December 31, 2022 and 2021, the Company recorded amortization expense of $1.4 million and $3.8 million, respectively. For the six months ended December 31, 2022 and 2021, the Company recorded amortization expense of $2.6 million and $7.8 million, respectively.

Future annual amortization expense consists of the following as of December 31, 2022:

---

| | |
|:---|:---|
| **(In thousands)**<br>**Fiscal Year Ending June 30,**  | **Amortization**<br>**Expense** |
| 2023 | $2095 |
| 2024 | 3874 |
| 2025 | 3840 |
| 2026 | 3673 |
| 2027 | 3535 |
| Thereafter  | 12622 |
|  | $29639 |

---

[**Table of Contents**](#TOC)

**Note 10. Long-Term Debt**

Long-term debt, net consisted of the following:

---

| | | |
|:---|:---|:---|
| <br>**(In thousands)** | **December 31,** <br>**2022** | **June 30,** <br>**2022** |
| 7.75% Senior Secured Notes due 2026 | $350000 | $350000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unamortized discount and other debt issuance costs  | (4070) | (4599) |
| 7.75% Senior Secured Notes due 2026, net | 345930 | 345401 |
| Second Lien Secured Loan Facility due 2026 ($190.0M Principal, $5.7M Exit Fee, and $27.5M and $22.0M accrued PIK interest at December 31, 2022 and June 30, 2022 respectively) | 223174 | 217721 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unamortized discount and other debt issuance costs  | (29633) | (32308) |
| Second Lien Secured Loan Facility due 2026, net | 193541 | 185413 |
| 4.50% Convertible Senior Notes due 2026 | 86250 | 86250 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unamortized discount and other debt issuance costs | (1866) | (2116) |
| 4.50% Convertible Senior Notes, net | 84384 | 84134 |
| $45.0 million Amended ABL Credit Facility  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt, net  | $623855 | $614948 |

---

The weighted average interest rate for the three months ended December 31, 2022 and 2021 was 9.1% and 8.9%, respectively. The weighted average interest rate for the six months ended December 31, 2022 and 2021 was 9.1% and 8.9%, respectively. As of December 31, 2022, the Company recorded interest payable of $8.8 million, which is included in the accrued expenses caption of the Consolidated Balance Sheet.

On April 22, 2021, the Company issued $350.0 million aggregate principal amount of the Notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act. The Notes bear interest semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2021, at a rate of 7.750% per annum in cash. The Notes will mature on April 15, 2026, unless earlier redeemed or repurchased in accordance with their terms.

On April 5, 2021, the Company entered into an Exchange Agreement with certain participating lenders to exchange a portion of their existing Term B Loans for Second Lien Loans pursuant to a new $190.0 million Second Lien Facility. On April 22, 2021, in connection with the issuance of the Notes and the entrance into the Amended ABL Credit Facility, which is discussed further below, the exchange between the Company and the participating lenders was consummated. From the Closing Date until the one-year anniversary of the Closing Date, the Second Lien Loans bear 10.0% PIK interest. Thereafter, the Second Lien notes will bear 5.0% cash interest and 5.0% PIK interest until maturity, except to the extent the Company elects to pay all or portion of the PIK interest in cash. To date, the Company has not paid any PIK interest in cash. The Second Lien Loans will mature on July 21, 2026. In connection with the Second Lien Facility, the Company issued to the Participating Lenders Warrants to purchase up to 8,280,000 shares of common stock of the Company at an exercise price of $6.88 per share. Refer to Note 13 "Warrants" for further information on the Warrants issued.

In connection with the Second Lien Facility, the Company is required to maintain at least $5.0 million in a deposit account at all times subject to control by the Second Lien Collateral Agent, and a minimum cash balance of $15.0 million as of the last day of each month. At December 31, 2022, the Company classified the $5.0 million required deposit account balance as restricted cash, which is included in other assets caption in the Consolidated Balance Sheet. The Second Lien Facility also contains an affirmative covenant requiring delivery of the Company's year-end financial statements, accompanied by an audit opinion that is not qualified, subject to customary exceptions, as to the status of the Company as a going concern.

[**Table of Contents**](#TOC)

In addition to the Notes Offering and the Second Lien Facility, on April 22, 2021, the Company entered into an amendment to that certain Credit and Guaranty Agreement, dated as of December 7, 2020 (such agreement as so amended, the "Amended ABL Credit Agreement"), among the Company, certain of its wholly-owned domestic subsidiaries party thereto, as borrowers or as guarantors, Wells Fargo Bank, National Association, as administrative agent and as collateral agent and the other lenders party thereto, for the purpose of, among other things, increasing the aggregate amount of the revolving credit facility from $30.0 million to $45.0 million and extending the maturity thereof to the fifth anniversary of the closing date of Notes Offering (subject to a springing maturity as set forth therein).

The Amended ABL Credit Agreement provides for a revolving credit facility (the "Amended ABL Credit Facility") that includes letter of credit and swing line sub-facilities. Borrowing availability under the Amended ABL Credit Facility is determined by a monthly borrowing base collateral calculation that is based on specified percentages of eligible accounts receivable less certain reserves and subject to certain other adjustments as set forth in the Amended ABL Credit Agreement. Availability is reduced by issuance of letters of credit as well as any borrowings. Loans outstanding under the Amended ABL Credit Agreement bear interest at a floating rate measured by reference to, at the Company's option, either an adjusted London Inter-Bank Offered Rate ("LIBOR") (subject to a floor of 0.75%) plus an applicable margin of 2.50% per annum, or an alternate base rate plus an applicable margin of 1.50% per annum. Unused commitments under the Amended ABL Credit Facility are subject to a per annum fee of 0.50% per annum, which fee increases to 0.75% per annum for any quarter during which the Company's average usage under the Amended ABL Credit Facility is less than $5.0 million.

On September 27, 2019, the Company issued $86.3 million aggregate principal amount of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Convertible Notes are senior unsecured obligations of the Company and bear interest at an annual rate of 4.50% payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2020. The Convertible Notes will mature on October 1, 2026, unless earlier repurchased, redeemed or converted in accordance with their terms. The Convertible Notes are convertible into shares of the Company's common stock at an initial conversion rate of 65.4022 shares per $1,000 principal amount of Convertible Notes (which is equivalent to an initial conversion price of approximately $15.29 per share), subject to adjustments upon the occurrence of certain events (but will not be adjusted for any accrued and unpaid interest). The Company may redeem all or a part of the Convertible Notes on or after October 6, 2023 at a redemption price equal to 100% of the principal amount of the Convertible Notes redeemed, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date, subject to certain conditions relating to the Company's stock price having been met. Following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or notice of redemption. The indenture covering the Convertible Notes contains certain other customary terms and covenants, including that upon certain events of default occurring and continuing, either the trustee or holders of at least 25% in principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable. In addition, if the Company ceases to be listed or quoted on any of The NYSE, The Nasdaq Global Select Market or The Nasdaq Global Market (or any of their respective successors), holders of the outstanding Convertible Notes will have the option to require the Company to repurchase for cash all of such holder's notes at 100% of the principal amount, plus accrued and unpaid interest. See Note 2 "The Business and Nature of Operations" for additional information regarding the out-of-compliance notices received from the NYSE.

In connection with the offering of the Convertible Notes, the Company also entered into privately negotiated "capped call" transactions with several counterparties. The capped call transaction will initially cover, subject to customary anti-dilution adjustments, the number of shares of common stock that initially underlie the Convertible Notes. The capped call transactions are expected to generally reduce the potential dilutive effect on the Company's common stock upon any conversion of the Convertible Notes with such reduction subject to a cap which is initially $19.46 per share.

[**Table of Contents**](#TOC)

Long-term debt amounts due, for the twelve-month periods ending December 31 are as follows:

---

| | |
|:---|:---|
| <br>**(In thousands)** | **Amounts Payable**<br>**to Institutions** |
| 2023 | $— |
| 2024 |  |
| 2025 |  |
| 2026 | 659424 |
| 2027 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total  | $659424 |

---

The long-term debt amounts due above include accrued PIK interest on the Second Lien Facility as of December 31, 2022. As of April 22, 2022, which is the one-year anniversary of the closing date of the Second Lien Facility, the Company may now elect to pay in cash any interest previously required to be paid in the form of PIK interest. To date, the Company has not paid any PIK interest in cash.

The outstanding Notes, Second Lien Facility, and Amended ABL Credit Facility amounts above are guaranteed by all of Lannett's significant wholly-owned domestic subsidiaries and are collateralized by substantially all present and future assets of the Company.

**Note 11. Legal, Regulatory Matters and Contingencies**

*Federal Investigation into the Generic Pharmaceutical Industry*

In November and December 2014, the Company and certain affiliated individuals and customers were served with grand jury subpoenas relating to a federal investigation of the generic pharmaceutical industry into possible violations of the Sherman Act. The subpoenas requested corporate documents of the Company relating to corporate, financial and employee information, communications or correspondence with competitors regarding the sale of generic prescription medications and the marketing, sale, or pricing of certain products, generally for the period of 2005 through the dates of the subpoenas.

The Company received a Civil Investigative Demand ("CID") from the Department of Justice on May 14, 2018. The CID requested information from 2009-present regarding allegations that the generic pharmaceutical industry engaged in market allocation, price fixing, payment of illegal remuneration and submission of false claims. The Company has responded to the CID.

Based on internal investigations performed to date, the Company believes that it has acted in compliance with all applicable laws and regulations. 

*Government Pricing*

On May 22, 2019, following an audit conducted by the Company, the Department of Veterans Affairs issued a Contracting Officer's Final Decision and Demand for Payment, assessing the sum of $9.4 million for overpayments by the Veteran's Administration ("VA") as a result of certain commercial customer prices that were not properly disclosed to the VA for the period of January 1, 2012 through June 30, 2016. In August 2019, the Company remitted payment to the VA and was indemnified from UCB S.A. for the portion of that related to the period prior to the acquisition of KUPI (January 1, 2012 to November 24, 2015) totaling $8.1 million. The VA requested additional information for the period of July 1, 2016 through March 2018. The Company is in the process of responding to the information request.

[**Table of Contents**](#TOC)

*State Attorneys General and Private Plaintiffs Antitrust and Consumer Protection Litigation*

In December 2016, the Connecticut Attorney General and various other State Attorneys General filed a civil complaint alleging that six pharmaceutical companies engaged in anti-competitive behavior. The Company was not named in the action and does not compete on the products that formed the basis of the complaint. The complaint was later transferred for pretrial purposes to the United States District Court for the Eastern District of Pennsylvania as part of a multidistrict litigation captioned In re: Generic Pharmaceuticals Pricing Antitrust Litigation (the "MDL"). On October 31, 2017, the State Attorneys General filed a motion for leave to amend their complaint to add numerous additional defendants, including the Company, and claims relating to 13 additional drugs. The District Court granted that motion on June 5, 2018. The State Attorneys General filed their amended complaint on June 18, 2018. The claim relating to Lannett involves alleged price-fixing for one drug, doxycycline monohydrate, but does not involve the pricing for digoxin. The State Attorneys General also allege that all defendants were part of an overarching, industry-wide conspiracy to allocate markets and fix prices generally. On August 15, 2019, the Court denied the defendants' joint motion to dismiss the overarching conspiracy claims but has yet to decide an individual motion filed by the Company to dismiss the overarching conspiracy claims as to it. On June 7, 2022, the Court granted a joint motion of all defendants to dismiss the federal claim of the State Attorneys General for disgorgement of defendants' allegedly ill-gotten gains, but denied defendants' motion to dismiss their parens patriae federal claims for injunctive relief due to lack of standing.

On May 10, 2019, the State Attorneys General filed a new lawsuit naming the Company and one of its employees as defendants, along with 33 other companies and individuals. The complaint again alleges an overarching conspiracy and contains claims for price-fixing and market allocation under the Sherman Act and related state laws. The complaint focuses on the conduct of another generic pharmaceutical company, and the relationships that company had with other generic companies and their employees. The specific allegations in this complaint against Lannett relate to the Company's sales of baclofen and levothyroxine. The complaint also names another current employee as a defendant, but the allegations pertain to conduct that occurred prior to their employment by Lannett. In June 2020, the State Attorneys General filed a third overarching conspiracy complaint involving scores of different drugs used primarily to treat dermatological conditions, including alleged price-fixing by the Company for acetazolamide. Both complaints have been added to the MDL.

In 2016 and 2017, the Company and certain competitors were named as defendants in a number of lawsuits filed by private plaintiffs alleging that the Company and certain generic pharmaceutical manufacturers have conspired to fix prices of generic digoxin, levothyroxine, ursodiol and baclofen. These cases are part of a larger group of more than 100 lawsuits generally alleging that over 30 generic pharmaceutical manufacturers and distributors conspired to fix prices for multiple different generic drugs in violation of the federal Sherman Act, various state antitrust laws, and various state consumer protection statutes. The United States also has been granted leave to intervene in the cases. On April 6, 2017, these cases were added to the MDL. The various plaintiffs are grouped into three categories - Direct Purchaser Plaintiffs, End Payer Plaintiffs, and Indirect Reseller Purchasers - and filed Consolidated Amended Complaints ("CACs") against the Company and the other defendants in August 2017.

The CACs naming the Company as a defendant involve generic digoxin, levothyroxine, ursodiol and baclofen. Pursuant to a court-ordered schedule grouping the 18 different drug cases into three separate tranches, the Company and other generic pharmaceutical manufacturer defendants in October 2017 filed joint and individual motions to dismiss the CACs involving the six drugs in the first tranche, including digoxin. In October 2018, the Court (with one exception) denied defendants' motions to dismiss plaintiffs' Sherman Act claims with respect to the drugs in the first tranche. In March 2019, the Company and other defendants filed answers to the Sherman Act claims. In addition, in February 2019, the Court dismissed certain of the plaintiffs' state law claims but denied the remainder of defendants' motions to dismiss and set a deadline of April 1, 2019 for certain plaintiffs to amend their existing complaints. Those plaintiffs amended their complaints, but further motions to dismiss the state-law claims remain pending.

Following the lead of the state Attorneys General, the Direct Purchaser Plaintiffs, End Payer Plaintiffs and Indirect Reseller Plaintiffs filed their own complaints in June 2018 alleging an overarching conspiracy relating to 14 generic drugs in the End Payer complaint and 15 generic drugs in the Indirect Reseller complaint. Although the complaints allege an overarching conspiracy with respect to all of the drugs identified, the specific allegations related to drugs the Company manufactures involve acetazolamide and doxycycline monohydrate.

[**Table of Contents**](#TOC)

In addition, between December 2019 and February 2020, the End Payer Plaintiffs, Indirect Reseller Purchasers, and Direct Purchaser Plaintiffs filed separate complaints alleging overarching, industry-wide price-fixing conspiracies modeled on the second one filed by the state Attorneys General. The new complaint involves 135 new drugs in addition to those named in previous complaints. As to the Company, the new drugs involved are pilocarpine HCL, triamterene HCTZ capsules, amantadine HCL, and oxycodone HCL. None of the defendants, including the Company, has responded yet to these new complaints.

Between January 2018 and December 2020, a number of opt-out parties filed individual complaints or otherwise commenced actions against the Company and dozens of other companies and individuals alleging an overarching conspiracy and individual conspiracies to fix the prices and allocate markets on scores of different drug products, including digoxin, doxycycline, levothyroxine, ursodiol and baclofen. The opt-out parties include various retailers, insurers and county governments, which have filed federal suits in Pennsylvania, New York, California, Minnesota and Texas. All of those complaints have been added to the MDL but none of the defendants, including the Company, has responded to any of the complaints. Other groups of insurers have commenced actions in Pennsylvania state court against the Company and other drug companies by filing writs of summons, which are not complaints but can serve to toll the running of statutes of limitations. Those state-court cases have not been added to the MDL, although the parties have agreed to stay those cases pending further developments in the MDL. One of the insurance state-court plaintiffs filed a motion to have its case removed from deferred status so it could be litigated simultaneously in the Philadelphia Court of Common Pleas, but the Court denied that motion on October 3, 2022, so the case currently remains in deferred status.

In June 2020, the Company and a number of other generic pharmaceutical manufacturers were named as defendants in a Statement of Claim in a proposed class proceeding in federal court in Toronto, Ontario, Canada. The case alleges a violation of Canada's Competition Act. The allegations are similar to those in the MDL alleging an overarching, industry-wide conspiracy to allocate markets and fix the price of generic drugs. That alleged conspiracy reached Canada because these same manufacturers also allegedly sell the majority of generic drugs in Canada. The Statement of Claim alleges that the conspiracy extends to the entire generic pharmaceutical market. The specific drugs identified with respect to the Company are: acetazolamide, baclofen, digoxin, doxycycline monohydrate, levothyroxine, and ursodiol. The Company has not yet responded to the Statement of Claim.

On July 13, 2020, the District Court overseeing the MDL selected as "bellwether" cases the second overarching conspiracy case filed by the state Attorneys General in May 2019 as well as individual-conspiracy cases filed by the Direct Purchaser Plaintiffs, End Payer Plaintiffs, and Indirect Reseller Purchasers involving the drugs clobetasol, clomipramine and pravastatin. The Company is a defendant only in the overarching conspiracy case. On February 9, 2021, the District Court vacated the order selecting the bellwether cases. Thereafter, the District Court re-designated the clobetasol and clomipramine cases as individual-conspiracy bellwethers, and on May 7, 2021, selected the third complaint filed by the state Attorneys General in June 2020 as the new overarching conspiracy bellwether case. On September 9, 2021, the state Attorneys General amended their bellwether complaint. To date, none of the bellwether cases have been scheduled for trial.

The Company believes that it acted in compliance with all applicable laws and regulations. Accordingly, the Company disputes the allegations set forth in these class actions and plans to vigorously defend itself against these claims.

[**Table of Contents**](#TOC)

*Shareholder Litigation*

In November 2016, a putative class action lawsuit was filed against the Company and two of its former officers in the federal district court for the Eastern District of Pennsylvania, alleging that the Company and two of its former officers damaged the purported class by making false and misleading statements regarding the Company's drug pricing methodologies and internal controls. In December 2017, counsel for the putative class filed a second amended complaint. The Company filed a motion to dismiss the second amended complaint in February 2018. In July 2018, the court granted the Company's motion to dismiss the second amended complaint. In September 2018, counsel for the putative class filed a third amended complaint alleging that the Company and two of its former officers made false and misleading statements regarding the impact of competition on prices and sales of certain of the Company's products, regarding the potential effects on the Company of regulatory investigations and antitrust litigation, and regarding the defendants' investigation of purported anticompetitive conduct. The Company filed a motion to dismiss the third amended complaint in November 2018. In May 2019, the court denied the Company's motion to dismiss the third amended complaint. In July 2019, the Company filed an answer to the third amended complaint. In October 2020, counsel for the putative class filed a motion for class certification. In March 2021, the Company filed a brief in opposition to the motion to certify the putative class. In August 2021, the court granted the motion to certify the proposed class, to appoint class representatives, and to appoint class counsel. In August 2021, the Company filed a petition for permission to appeal the court's class certification order. In September 2021, counsel for the class filed a response in opposition to the Company's petition. In November 2021, the United States Court of Appeals for the Third Circuit granted the Company's petition for permission to appeal the class certification order. In January 2022, the Third Circuit granted the Company's motion to stay the case pending a decision on the interlocutory appeal. The Company believes it acted in compliance with all applicable laws and continues to vigorously defend itself from these claims. The Company cannot reasonably predict the outcome of the suit at this time.

*Sandoz, Inc.*

On July 20, 2020, Sandoz, Inc. ("Sandoz") filed a complaint in federal court in Philadelphia, alleging claims for tortious interference with contract, unfair competition and conversion of confidential information, arising out of Cediprof, Inc.'s ("Cediprof") termination of Sandoz's contract to distribute levothyroxine tablets in the United States and certain territories. Along with the complaint, Sandoz filed a motion for a temporary restraining order and preliminary injunction, seeking to enjoin the Company from commencing the distribution of levothyroxine tablets on August 3, 2020. On the same day, Sandoz filed a separate complaint and application for a temporary restraining order and preliminary injunction against Cediprof in federal court in New York, seeking to prevent Cediprof from selling its levothyroxine tablets in the United States and certain of its territories to anyone other than Sandoz. On July 27, 2020, the New York court held a hearing and denied Sandoz's application for a temporary restraining order, ruling Sandoz had failed to establish irreparable harm. Sandoz subsequently dismissed the complaint and is proceeding against Cediprof in an Arbitration in New York, where the Company has agreed to indemnify Cediprof. On July 28, 2020, the Philadelphia court held a hearing and denied Sandoz's application for a temporary restraining order, ruling that Sandoz had failed to establish irreparable harm and failed to establish that it is likely to succeed on the merits of its claim against Lannett. On October 5, 2020, the Company filed a motion to dismiss the complaint. On December 28, 2020, the Court granted in part and denied in part the motion, dismissing certain of the claims. The Company has filed a motion to stay the case pending the Arbitration of the Sandoz/Cediprof dispute. On January 11, 2021, the Company filed an answer and counterclaim to the complaint. Upon the conclusion of fact discovery, the Court entered an order on July 16, 2021 staying the remaining deadlines in the case pending the outcome of the Arbitration between Sandoz and Cediprof, which began on January 31, 2022. On August 5, 2022, the Arbitrator issued a final award, finding that Cediprof had breached the Sandoz contract and determining that Sandoz is entitled to lost profits, among other damages. The portion of the award subject to indemnification from the Company amounted to $10.9 million, which the Company has accrued as of June 30, 2022. The Company's indemnification obligation will only be triggered if and when Cediprof pays the award. On November 4, 2022, Cediprof filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code. By virtue of the automatic stay arising upon the filing of the bankruptcy petition, collection efforts against Cediprof are stayed pending the resolution of the bankruptcy proceeding.

[**Table of Contents**](#TOC)

*Ranitidine Oral Solution, USP*

On June 1, 2020, a class action complaint was served upon the Company and approximately forty-five (45) other companies asserting claims for personal injury arising from the presence of NDMA in Ranitidine product, which was consolidated in a multidistrict litigation ("MDL") pending in the United States District Court for the Southern District of Florida. Following the filing of a first amended complaint, the Company filed a motion to dismiss, which was granted and resulted in a dismissal of all claims with prejudice based on federal preemption. The Plaintiffs filed an appeal to the Eleventh Circuit Court of Appeals, which has not yet been ruled upon.

Separately, several lawsuits were filed in various state courts by state government, city government, and several private parties asserting various consumer protection and/or personal injury claims (in the case of individual plaintiffs) regarding the presence of NDMA in Ranitidine products. The Company has filed motions to dismiss in all state cases, some of which were granted and other of which were denied. The Company denies all liability in pending cases.

*Other Litigation Matters*

The Company is also subject to various legal proceedings arising out of the normal course of its business including, but not limited to, product liability, intellectual property, patent infringement claims and antitrust matters. It is not possible to predict the outcome of these various proceedings. An adverse determination in any of these proceedings or in any of the proceedings described above in the future could have a significant impact on the financial position, results of operations and cash flows of the Company.

**Note 12. Commitments** 

*Leases* 

At December 31, 2022 and June 30, 2022, the Company had a ROU lease asset of $9.3 million and $9.6 million, respectively, and an operating lease liability of $11.5 million and $12.1 million, respectively. The current balance of the operating lease liability at December 31, 2022 was $2.1 million.

Components of lease costs are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended**  | **Six Months Ended**  |
| | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
| <br>**(In thousands)** | **2022** | **2021** | **2022** | **2021** |
| Operating lease cost | $466 | $444 | $932 | $905 |
| Variable lease cost | 41 | 16 | 79 | 57 |
| Short-term lease cost (a) | 144 | 83 | 228 | 152 |
| Total | $651 | $543 | $1239 | $1114 |

---

______________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Not recorded on the Consolidated Balance Sheet

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended**  | **Six Months Ended**  |
| | **December 31,**  | **December 31,**  |
| <br>**(In thousands)** | **2022** | **2021** |
| **Cash paid for amounts included in the measurement of lease liabilities:** |  |  |
| Operating cash flows from operating leases | $1104 | $1084 |

---

[**Table of Contents**](#TOC)

Weighted-average remaining lease term and discount rate for our operating leases are as follows:

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended**  | **Six Months Ended**  |
|  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** |
| Weighted-average remaining lease term | 8<br> years | 9<br> years |
| Weighted-average discount rate | 8.5% | 8.5% |

---

Maturities of lease liabilities by fiscal year for our operating leases are as follows:

---

| | |
|:---|:---|
| **(In thousands)** | **Amounts Due** |
| 2023 | $1041 |
| 2024 | 2083 |
| 2025 | 2103 |
| 2026 | 2124 |
| 2027 | 2145 |
| Thereafter | 6368 |
| Total lease payments | 15864 |
| Less: Imputed interest | 4349 |
| Present value of lease liabilities | $11515 |

---

*Other Commitments*

In Fiscal 2020, the Company executed a License and Collaboration Agreement with North South Brother Pharmacy Investment Co., Ltd. and HEC Group PTY, Ltd. (collectively, "HEC") to develop an insulin glargine product that would be biosimilar to Lantus Solostar. Under the terms of the deal, among other things, the Company shall fund up to the initial $32.0 million of the development costs and split 50/50 any development costs in excess thereof. As of December 31, 2022, the Company has incurred approximately $9.3 million of development costs towards the $32.0 million commitment made by the Company. As we have completed dosing of subjects in the clinical trial at this time, we expect development funding will be well less than $32.0 million. Lannett shall receive an exclusive license to distribute and market the product in the United States upon FDA approval under the 50/50 profit split for the first ten years following commercialization, followed by a 60/40 split in favor of HEC for the following five years.

On February 8, 2021, the Company executed a License and Collaboration Agreement and a Supply Agreement with Sunshine Lake Pharma Co., Ltd. an HEC Group company ("Sunshine") with respect to the development of a biosimilar insulin aspart product. Under the terms of the deal, among other things, the Company shall fund up to the initial $32.0 million of the development costs, provided that if total development and other costs paid by Lannett are less than $32.0 million then the difference will be paid to Sunshine over the first year of commercialization. As of December 31, 2022, the Company has incurred approximately $2.2 million towards the $32.0 million commitment made by the Company. The parties shall negotiate the sharing of any development costs in excess of $32.0 million. Lannett shall receive an exclusive license to distribute and market the product in the United States upon FDA approval under the 50/50 profit split for the first ten years following commercialization, followed by a 60/40 split in favor of Sunshine for the following five years.

In conjunction with the HEC collaboration efforts to develop biosimilar insulin glargine and aspart, the Company also separately entered into two Customization and Supply Agreements with Ypsomed AG ("Ypsomed") in October 2020 and July 2021 to develop, manufacture and supply an injection device to be used with both insulin products. In April 2022, the Company executed an amendment to the Customization and Supply Agreements to allow Ypsomed to expand their production capacity to meet the anticipated demand. Under the terms of the deal, the Company is required to pay 14 million Swiss Francs ("CHF") to Ypsomed over various future milestone dates to fund the capacity expansion in exchange for a predetermined discount on future purchases of the injection device. In April 2022, The Company paid Ypsomed 4.0 million CHF, the equivalent of approximately $4.3 million, which is recorded in the other assets caption of the Consolidated Balance Sheet as of December 31, 2022. The remaining 4.0 million and 6.0 million CHF payments are to be paid in installments in calendar years 2023 and 2024, respectively.

[**Table of Contents**](#TOC)

In Fiscal 2017, the Company signed an agreement with a third-party company operating in the online pharmaceutical business, under which the Company agreed to provide up to $15.0 million in revolving loans for the purpose of expansion and other business needs. Any outstanding balance under the loan would bear interest at 2.0% and be due seven years from the date of the agreement. As of 12/31/2022, after a review of the third-party's current financial condition as well as their projected liquidity levels, the Company determined that it is more likely than not that the third party will be unable to repay the outstanding loan. Therefore, the Company recorded a full write-off of the loan receivable of $6.8 million during the second quarter of Fiscal 2023.

**Note 13. Warrants**

In connection with the Second Lien Facility, the Company issued to the Participating Lenders warrants to purchase up to 8,280,000 shares of common stock of the Company (the "Warrants") at an exercise price of $6.88 per share. The Warrants were issued on April 22, 2021 with an eight-year term. The Participating Lenders received registration rights with respect to the shares of common stock of the Company to be received upon exercise of the Warrants. The Company concluded that the Warrants were indexed to its own stock and, therefore, are classified as an equity instrument. In accordance with ASC 470, *Debt*, the Company allocated the proceeds of the Second Lien Facility issuance based on the relative fair value of the debt instrument and the Warrants separately at the time of issuance, which was determined using the Black-Scholes valuation model. The relative fair value allocated to the Warrants was $24.4 million at the issuance date.

The holders of the Warrants are entitled to receive dividends or distributions of any kind made to the common stockholders to the same extent as if the holder had exercised the Warrant into common stock. Although the Company did not issue or declare dividends during the period, the Warrants are considered participating securities under ASC 260, *Earnings per share*, for purposes of calculating earnings (loss) per share under the two-class method. Refer to Note 14 "Loss Per Common Share" for further details of the two-class method and the Company's calculation of earnings (loss) per share.

**Note 14. Loss Per Common Share**

A reconciliation of the Company's basic and diluted loss per common share was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended**  | **Three Months Ended**  |
| | **December 31,**  | **December 31,**  |
| <br>**(In thousands, except share and per share data)** | **2022** | **2021** |
| **Numerator:** |  |  |
| Net loss | $(36308) | $(81085) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income allocated to participating securities for the Warrants |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expenses applicable to the Convertible Notes, net of tax |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs applicable to the Convertible Notes, net of tax |  |  |
| Adjusted "if-converted" net loss | $(36308) | $(81085) |
| **Denominator:** |  |  |
| Basic weighted average common shares outstanding | 41170839 | 40358127 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of potentially dilutive options, restricted stock awards and performance-based shares |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of conversion of the Convertible Notes |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of participating securities for the Warrants |  |  |
| Diluted weighted average common shares outstanding  | 41170839 | 40358127 |
| Loss per common share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.88) | $(2.01) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.88) | $(2.01) |

---

[**Table of Contents**](#TOC)

---

| | | |
|:---|:---|:---|
| | **Six Months Ended**  | **Six Months Ended**  |
| | **December 31,**  | **December 31,**  |
| <br>**(In thousands, except share and per share data)** | **2022** | **2021** |
| **Numerator:**  |  |  |
| Net loss | $(64327) | $(103427) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income allocated to participating securities for the Warrants |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expenses applicable to the Convertible Notes, net of tax |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs applicable to the Convertible Notes, net of tax |  |  |
| Adjusted "if-converted" net loss | $(64327) | $(103427) |
| **Denominator:**  |  |  |
| Basic weighted average common shares outstanding  | 41056607 | 40142974 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of potentially dilutive options, restricted stock awards and performance-based shares |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of conversion of the Convertible Notes |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of participating securities for the Warrants |  |  |
| Diluted weighted average common shares outstanding  | 41056607 | 40142974 |
| Loss per common share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic  | $(1.57) | $(2.58) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted  | $(1.57) | $(2.58) |

---

In accordance with ASC 260, *Earnings per share*, the Company computes earnings (loss) per share using the two-class method, which requires an allocation of earnings between the holders of common stock and the Company's participating security holders. Basic earnings (loss) per share is calculated by dividing net income (loss) available to common stockholders, which excludes the income allocated to participating security holders, by the basic weighted average common shares outstanding. For purposes of determining diluted earnings per share, the Company further adjusts the basic earnings per share to include the effect of potentially dilutive shares outstanding, including options, restricted stock awards, performance-based shares, the Convertible Notes, and the Warrants. In this calculation, the Company reallocates net income based on the rights of each potentially dilutive share and will report the most dilutive earnings (loss) per share. Because the Warrants do not participate in losses, the Company will allocate undistributed earnings when calculating basic and diluted earnings per share in periods of net income only. The effect of the Warrants is excluded from the calculation of basic and diluted loss per share for the three and six months ended December 31, 2022 and 2021.

The number of anti-dilutive shares that have been excluded in the computation of diluted earnings per share for the three and six months ended December 31, 2022 and 2021 were 7.3 million and 8.1 million, respectively. The effect of potentially dilutive shares was excluded from the calculation of diluted loss per share in the three and six months ended December 31, 2022 and 2021 because the effect of including such securities would be anti-dilutive.

**Note 15. Share-based Compensation**

At December 31, 2022, the Company had two share-based employee compensation plans (the 2014 Long-Term Incentive Plan ("LTIP") and the 2021 LTIP). Together these plans authorized an aggregate total of 8.0 million shares to be issued. As of December 31, 2022, the plans have a total of 1.5 million shares available for future issuances.

Historically, the Company has issued share-based compensation awards with a vesting period ranging up to 3 years and a maximum contractual term of 10 years. The Company issues new shares of stock when stock options are exercised. As of December 31, 2022, there was $5.3 million of total unrecognized compensation cost related to non-vested share-based compensation awards. That cost is expected to be recognized over a weighted average period of 1.2 years.

[**Table of Contents**](#TOC)

The target award value mix in Fiscal 2022 for Named Executive Officers ("NEOs") was 50% performance shares, 30% restricted stock, and 20% provided in the form of a cash-based incentive where the value varies based on changes in our stock price over the three-year period ending June 30, 2024. In the first quarter of Fiscal 2023, the Compensation Committee approved the granting of 50% of the target long-term incentive for Fiscal 2023 (calculated based on the NEO's Fiscal 2022 salary) in the form of a cash-based retention award, which was paid in September 2022. In the second quarter of Fiscal 2023, certain other employees were granted a cash-based incentive award, which totaled $1.3 million and was paid in October 2022. The cash-based retention award was paid as a result of the potential dilution associated with granting equity incentives; however, the awards are subject to a 36-month service-based clawback. The clawback on one-third of the retention awards will expire annually based on continued service. The Company will recognize the expense on the awards across the three-year clawback period and prepaid expense of approximately $1.4 million and $2.5 million is included in other current assets and other assets on the Consolidated Balance Sheet at December 31, 2022, respectively. The remaining 50% of the target long-term incentive for Fiscal 2023 was re-allocated to the target of each NEO's performance-based short-term incentive plan.

*Stock Options*

The Company measures share-based compensation costs for options using the Black-Scholes option pricing model, which includes the use of various weighted average assumptions to estimate the fair values of stock options granted. Expected volatility is based on the historical volatility of the price of our common shares during the historical period equal to the expected term of the option. The Company uses historical information to estimate the expected term, which represents the period of time that options granted are expected to be outstanding. The risk-free rate for the period equal to the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The forfeiture rate assumption is the estimated annual rate at which unvested awards are expected to be forfeited during the vesting period. This assumption is based on our actual forfeiture rate on historical awards. Periodically, management will assess whether it is necessary to adjust the estimated rate to reflect changes in actual forfeitures or changes in expectations. Additionally, the expected dividend yield is typically equal to zero, as the Company has not historically issued a dividend.

There were no stock options granted during the six months ended December 31, 2022 and 2021. A stock option summary as of December 31, 2022 and changes during the six months then ended is presented below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**(In thousands, except for weighted average price and life data)** | **&nbsp;&nbsp;&nbsp;&nbsp;**<br>**Awards** | <br>**Weighted-**<br>**Average**<br>**Exercise**<br>**Price** | <br>**Aggregate**<br>**Intrinsic**<br>**Value** | **Weighted**<br>**Average**<br>**Remaining**<br>**Contractual**<br>**Life (yrs.)** |
| Outstanding at June 30, 2022 | 935 | $8.94 | $— | 6.5 |
| Forfeited, expired or repurchased  | (23) | $8.13 |  |  |
| Outstanding at December 31, 2022 | 912 | $8.96 | $— | 6.1 |
| Vested and expected to vest at December 31, 2022 | 912 | $8.96 | $— | 6.1 |
| Exercisable at December 31, 2022 | 710 | $9.73 | $— | 5.9 |

---

[**Table of Contents**](#TOC)

*Restricted Stock*

The Company measures restricted stock compensation costs based on the stock price at the grant date less an estimate for expected forfeitures. The annual forfeiture rate used to calculate compensation expense was 6.5% for the six months ended December 31, 2022 and 2021.

A summary of restricted stock awards as of December 31, 2022 and changes during the six months then ended, is presented below:

---

| | | | |
|:---|:---|:---|:---|
| <br>**(In thousands, except for weighted average price data)** | <br>**Awards** | **Weighted**<br>**Average Grant-date**<br>**Fair Value** | <br>**Aggregate**<br>**Intrinsic Value** |
| Non-vested at June 30, 2022 | 1355 | $5.28 |  |
| Vested  | (551) | 5.46 | $318 |
| Forfeited  | (23) | 4.97 |  |
| Non-vested at December 31, 2022 | 781 | $5.17 |  |

---

*Performance-Based Shares*

The Company grants performance-based awards to certain key executives. The stock-settled awards will cliff vest based on a three-year performance measurement period. Awards issued prior to July 2021 are based on relative Total Shareholder Return ("TSR") over a three-year period, which, in accordance with ASC 718, *Compensation – Stock Compensation*, are considered awards tied to market conditions. Half of the performance shares granted in July 2021 will be tied to our relative TSR, consistent with awards granted in prior years, with the other half tied to a variety of strategic portfolio goals, which, in accordance with ASC 718, *Compensation – Stock Compensation*, are considered awards tied to performance conditions. The Company measures share-based compensation cost for TSR awards using a Monte-Carlo simulation model. Compensation cost for awards tied to strategic portfolio goals is measured using the stock price at the grant date and is recognized based on performance at target award levels. However, in accordance with ASC 718, *Compensation – Stock Compensation*, the Company will assess the probability that the strategic portfolio goals will be met and adjust the cumulative compensation cost recognized accordingly at each reporting period.

There were no changes to the outstanding performance-based share awards during the six months ended December 31, 2022.

*Employee Stock Purchase Plan*

In February 2003, the Company's stockholders approved an Employee Stock Purchase Plan ("2003 ESPP"), under which the Company is authorized to issue 1.1 million shares of the Company's common stock. The 2003 ESPP was implemented on April 1, 2003 and is qualified under Section 423 of the Internal Revenue Code. In January 2022, the stockholders of the Company approved a new ESPP ("2022 ESPP" and, together with the 2003 ESPP, "ESPPs"). The Company is authorized to issue an additional 1.5 million shares of the Company's common stock under the 2022 ESPP, which is qualified under Section 423 of the Internal Revenue Code. During the six months ended December 31, 2022 and 2021, 177 thousand shares and 107 thousand shares were issued under the ESPPs, respectively. As of December 31, 2022, 1.5 million total cumulative shares have been issued under the ESPPs. Employees eligible to participate in the ESPP may purchase shares of the Company's stock at 85% of the lower of the fair market value of the common stock on the first day of the calendar quarter, or the last day of the calendar quarter. Under the ESPP, employees can authorize the Company to withhold up to 10% of their compensation during any quarterly offering period, subject to certain limitations.

[**Table of Contents**](#TOC)

The following table presents the allocation of share-based compensation costs recognized in the Consolidated Statements of Operations by financial statement line item:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended**  | **Three Months Ended**  | **Six Months Ended**  | **Six Months Ended**  |
| | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
| <br>**(In thousands)** | **2022** | **2021** | **2022** | **2021** |
| Selling, general and administrative expenses | $1392 | $2115 | $2836 | $4812 |
| Research and development expenses | 28 | 27 | 56 | 122 |
| Cost of sales  | 112 | 167 | 219 | 393 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total  | $1532 | $2309 | $3111 | $5327 |
| Tax benefit at statutory rate  | $345 | $519 | $700 | $1199 |

---

**Note 16. Employee Benefit Plan**

The Company has a 401(k) defined contribution plan (the "Plan") covering substantially all employees. Pursuant to the Plan provisions, the Company is required to make matching contributions equal to 50% of each employee's contribution, not to exceed 4% of the employee's compensation for the Plan year. Contributions to the Plan were $0.2 million during each of the three months ended December 31, 2022 and 2021. Contributions to the Plan were $0.6 million and $0.5 million during the six months ended December 31, 2022 and 2021, respectively.

In Fiscal 2020, the Company implemented a non-qualified deferred compensation plan for certain senior-level management and executives. The non-qualified deferred compensation plan allows certain eligible employees to defer additional pre-tax earnings for retirement, beyond the IRS limits in place under the Plan. Contributions to the non-qualified deferred compensation plan during the three and six months ended December 31, 2022 were not material.

**Note 17. Income Taxes**

The federal, state and local income tax expense for the three months ended December 31, 2022 was $32 thousand compared to income tax benefit of $1.4 million for the three months ended December 31, 2021. The effective tax rates for the three months ended December 31, 2022 and 2021 were (0.1)% and 1.7%, respectively.

The federal, state and local income tax expense for the six months ended December 31, 2022 was $66 thousand compared to income tax benefit of $1.4 million for the six months ended December 31, 2021. The effective tax rates for the six months ended December 31, 2022 and 2021 were (0.1)% and 1.4%, respectively.

The Company may recognize the tax benefit from an uncertain tax position claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

As of December 31, 2022 and June 30, 2022, the Company has total unrecognized tax benefits of $4.6 million, of which $4.5 million would impact the Company's effective tax rate for each period, if recognized. As a result of the positions taken during the period, the Company has not recorded any material interest and penalties for the period ended December 31, 2022 in the statement of operations and no cumulative interest and penalties have been recorded either in the Company's statement of financial position as of December 31, 2022 and June 30, 2022. The Company will recognize interest accrued on unrecognized tax benefits in interest expense and any related penalties in operating expenses.

[**Table of Contents**](#TOC)

The Company files income tax returns in the United States federal jurisdiction and various states. The Company's federal tax returns for Fiscal 2014 and prior generally are no longer subject to review as such years are closed. The Company's Fiscal 2015 through 2017, 2019, 2020 and 2021 federal returns are currently under examination by the Internal Revenue Service ("IRS"). As part of a lengthy process, the Company has received various Information Document Requests and Notices of Proposed Adjustment with respect to positions taken in certain income tax issues, including an accounting method change related to chargebacks and rebates that the IRS is proposing to disallow. We are in the process of assessing the impact of these notices and preparing a response to the IRS. We believe that it is more likely than not that our positions will ultimately be sustained upon further examination, and, if necessary, will contest any addition tax determined to be owed; however, an adverse outcome could have a material impact to the Company's Consolidated Statements of Operations and financial position. In September 2022, the IRS notified the Company that a portion of its income tax receivables balance will be held until the completion of the examination of its federal tax returns. As such, the balance expected to be held by the IRS is classified as income taxes receivable on the Company's Consolidated Balance Sheet as of December 31, 2022.

**Note 18. Related Party Transactions**

The Company had sales of $0.3 million and $0.4 million during the three months ended December 31, 2022 and 2021, respectively, to a generic distributor, Auburn Pharmaceutical Company ("Auburn"), which is a member of the Premier Buying Group. Sales to Auburn for the six months ended December 31, 2022 and 2021 were $0.6 million for each period. Jeffrey Farber, a board member until January 25, 2023 and stockholder owning more than five percent of the Company's stock, is the owner of Auburn. Accounts receivable includes amounts due from Auburn of $0.3 million at December 31, 2022 and June 30, 2022.

**Note 19. Assets Held for Sale**

*State Road Facility*

In September 2022, the Company signed a listing and sale agreement to engage a broker to sell its State Road facility and certain equipment at the facility. The Company adjusted the assets to fair value less costs to sell, which resulted in a $4.7 million impairment charge. As of December 31, 2022, the assets identified for sale at the State Road facility, totaling $1.3 million, were recorded in the assets held for sale caption in the Consolidated Balance Sheets.

[**Table of Contents**](#TOC)

**Note 20. Subsequent Events**

On January 25, 2023, the stockholders of the Company approved a proposed amendment to the Company's Certificate of Incorporation to effect a reverse stock split (the "Reverse Stock Split") of the issued and outstanding shares of common stock, par value $0.001 per share, of the Company at a ratio of between 1-for-3 and 1-for-5, inclusive. Per the approved proposal, the Board of Directors has sole discretion to select a ratio at any whole number in the range.

On January 25, 2023, the Board of Directors approved a 1-for-4 reverse stock split and the Company plans to file an amendment to our Certificate of Incorporation to effectuate the reverse stock split on February 6, 2023. The Company's common stock will begin trading on a split-adjusted basis on February 7, 2023. Beginning in the third quarter of Fiscal 2023, earnings per share will be retroactively restated for all periods presented.

The following table presents pro forma loss per share on a post-reverse split basis for the three and six months ended December 31, 2022 and 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **(UNAUDITED)** | **(UNAUDITED)** | **(UNAUDITED)** | **(UNAUDITED)** |
| | **Three Months Ended**  | **Three Months Ended**  | **Six Months Ended**  | **Six Months Ended**  |
| | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
| <br>**(In thousands, except share and per share data)** | **2022** | **2021** | **2022** | **2021** |
| Net loss | $(36308) | $(81085) | $(64327) | $(103427) |
| Basic weighted average common shares outstanding | 10292710 | 10089532 | 10264152 | 10035744 |
| Diluted weighted average common shares outstanding | 10292710 | 10089532 | 10264152 | 10035744 |
| Loss per common share |  |  |  |  |
| Basic | $(3.53) | $(8.04) | $(6.27) | $(10.31) |
| Diluted | $(3.53) | $(8.04) | $(6.27) | $(10.31) |

---

[**Table of Contents**](#TOC)

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*Cautionary Statement About Forward-Looking Statements*

This Report on Form 10-Q and certain information incorporated herein by reference contains forward-looking statements which are not historical facts made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, acquisition-related challenges, the regulatory environment, interest rate fluctuations, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other risks detailed from time to time in our filings with the Securities and Exchange Commission ("SEC"). These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements which speak only as of the date made. Lannett is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise and other events or factors, many of which are beyond our control, including those resulting from such events, or the prospect of such events, such as public health issues including health epidemics or pandemics, such as the outbreak of the novel coronavirus ("COVID-19"), whether occurring in the United States or elsewhere, which could disrupt our operations, disrupt the operations of our suppliers and business development and other strategic partners, disrupt the global financial markets or result in political or economic instability.

The following information should be read in conjunction with the consolidated financial statements and notes in Part I, Item 1 of this Quarterly Report and with Management's Discussion and Analysis of Financial Condition and Results of Operations contained in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2022. All references to "Fiscal 2023" shall mean the fiscal year ending June 30, 2023 and all references to "Fiscal 2022" shall mean the fiscal year ended June 30, 2022.

**Company Overview**

Lannett Company, Inc. (a Delaware corporation) and its subsidiaries (collectively, the "Company," "Lannett," "we" or "us") primarily develop, manufacture, package, market and distribute solid oral and extended release (tablets and capsules), topical, liquids, nasal and oral solution finished dosage forms of drugs, generic forms of both small molecule and biologic medications, that address a wide range of therapeutic areas. Certain of these products are manufactured by others and distributed by the Company. Additionally, the Company is pursuing partnerships, research contracts and internal expansion for the development and production of other dosage forms including: ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable and oral dosages.

The Company operates a pharmaceutical manufacturing plant in Seymour, Indiana. During Fiscal 2022, the Company completed the sale of its Silarx facility in Carmel, New York. In connection with the sale, the buyer will continue to produce certain products on behalf of the Company at the Carmel facility while the Company completes the transfer of such products to its Seymour, Indiana plant.

The Company's customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations.

[**Table of Contents**](#TOC)

**NYSE Notices of Failure to Satisfy a Continued Listing Rule or Standard**

On March 2, 2022, we received notice from the New York Stock Exchange (the "NYSE") that we were no longer in compliance with the NYSE continued listing standards, set forth in Section 802.01B of the NYSE's Listed Company Manual, because the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50.0 million and, at the same time, our shareholders' equity was less than $50.0 million. If the Company's average global market capitalization over a consecutive 30 trading-day period drops below $15.0 million, the NYSE will initiate delisting proceedings. As of January 31, 2022, the 30 trading-day average global market capitalization of the Company was approximately $26.4 million, and the Company's absolute market capitalization was approximately $23.7 million. In accordance with the NYSE listing requirements, we submitted a plan that demonstrates how we expect to return to compliance with Section 802.01B within 18 months. On May 26, 2022, the Company received notice from the NYSE that the plan was accepted. The NYSE will be performing quarterly reviews during the 18 months from the Company's receipt of the notice for compliance with the goals and initiatives as outlined in the Company's plan. Failure to satisfy the requisite goals or initiatives may result in the Company being subject to NYSE trading suspension at that time. The Company is required to achieve the minimum continued listing standards of either average global market capitalization over a consecutive 30 trading-day period of $50 million or total stockholders' equity of $50 million at the completion of the 18-month plan period, and failure to achieve any of the minimum requirements at the end of the 18-month period may result in the Company being suspended by the NYSE, which may make an application to the SEC to delist the Company's common stock. There can be no assurances that the Company will maintain compliance with the plan.

In addition, on March 14, 2022, the Company received a second notice from the NYSE that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE's Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 per share over a consecutive 30 trading-day period. In order to regain compliance, on the last trading day of any calendar month during the cure period or on the last business day of the six-month cure period, the Company's shares of common stock must demonstrate (i) a closing price of at least $1.00 per share and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on such date. On January 25, 2023, the stockholders of the Company and the Board of Directors approved a 1-for-4 reverse stock split, and the Company plans to file an amendment to our Certificate of Incorporation to effectuate the reverse stock split on February 6, 2023. The Company's common stock will begin trading on a split-adjusted basis on February 7, 2023. If the Company's stock price exceeds $1.00 on a split-adjusted basis for at least 30 trading days following the reverse stock split, the price condition will be deemed cured. However, there can be no assurances that the Company will meet this continued listing standard within the specified cure period.

If we are unable to satisfy the NYSE criteria for continued listing, our common stock would be subject to delisting. A delisting of our common stock could negatively impact our reputation and, consequently, our business by, among other things, reducing the liquidity and market price of our common stock; reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise equity financing; decreasing the amount of news and analyst coverage of the Company; and limiting our ability to issue additional securities or obtain additional financing in the future. In addition, if the Company ceases to be listed or quoted on any of The NYSE, The Nasdaq Global Select Market or The Nasdaq Global Market (or any of their respective successors), holders of the outstanding 4.50% Convertible Senior Notes (the "Convertible Notes") will have the option to require the Company to repurchase for cash all of such holder's notes at 100% of the principal amount, plus accrued and unpaid interest. An acceleration of our debt maturities would put significant pressure on our liquidity and ability to continue to operate as a going concern; however, in the event of a delisting or likely delisting, the Company intends to work proactively and collaboratively with its debt holders to amend its credit documents and indentures or pursue other alternative plans that are probable of execution in order to avoid a default and acceleration of the Company's indebtedness.

[**Table of Contents**](#TOC)

**2022 Restructuring Plan** 

On December 15, 2022, the Company authorized a restructuring and cost savings plan (the "2022 Restructuring Plan") to streamline and realign our operations to ensure the continued progression of our existing pipeline and future growth. The 2022 Restructuring Plan includes operational improvements and cost efficiencies as well as engagement with more external partners and technology providers, globally, to execute on our R&D plans and operations.

The total reduction in headcount for the 2022 Restructuring Plan is expected to be approximately 60 positions and is expected to be completed by the end of Fiscal 2023. The Company estimates that it will incur approximately $3 million in severance-related costs in connection with the 2022 Restructuring Plan.

In connection with the shift in our R&D operations, the Company also anticipates exiting our State Road and Torresdale facilities in Philadelphia, Pennsylvania by the end of our current fiscal year. In the first quarter of Fiscal 2023, the Company recorded an impairment charge of $4.7 million to adjust the State Road facility and certain equipment to fair value less costs to sell and the remaining assets of $1.3 million were recorded in the assets held for sale caption in the Consolidated Balance Sheet. In the second quarter of Fiscal 2023, the Company recorded an impairment charge of $6.0 million to adjust the Torresdale facility to its approximate fair value.

**Supply Chain** 

The COVID-19 pandemic has contributed, in part, to global supply chain disruptions, shortages, and recent inflationary pressures. While the Company is still able to receive sufficient inventory of the key materials needed across its network, the Company continues to experience pressure on its supply chain, including shipping delays, higher prices from suppliers, and reduced availability of materials, particularly excipients and packaging components. To date, the supply chain pressure has not had a material impact on the Company's results of operations. However, the Company is regularly communicating with its suppliers, third-party partners, customers, healthcare providers and government officials in order to respond rapidly to any issues as they arise. The longer the current situation continues, it is more likely that the Company may experience some sort of material interruption to our supply chain, and such an interruption could adversely affect our business, including but not limited to, our ability to timely manufacture and distribute our products.

**Climate Change**

The Company believes in a more sustainable future with a reduced environmental footprint and a general view towards reducing our effect on the climate while maintaining our focus on providing affordable medicines to our customers and ultimately the patients who depend on them. The Company has begun to consider climate-related risks that are pertinent to the Company. Our aspiration is to reduce our environmental footprint. However, related efforts may result in increased costs to the Company including, but not limited to, capital investments, additional management and compliance costs, and reduced output, all of which may be material. Costs incurred by our suppliers and vendors to comply with their own sustainability commitments may also be passed through the supply chain resulting in higher operational costs to the Company. Climate change and the associated risks and regulations are expected to continue to evolve over time and could materially impact the Company's results of operations and cash flows in any given year. The Company monitors such matters and strives to address them in a timely manner.

[**Table of Contents**](#TOC)

**Results of Operations - Three months ended December 31, 2022 compared with the three months ended December 31, 2021**

Net sales decreased 6% to $80.9 million for the three months ended December 31, 2022. The table below identifies the Company's net product sales by medical indication for the three months ended December 31, 2022 and 2021.

---

| | | |
|:---|:---|:---|
| | **December 31,**  | **December 31,**  |
| **(In thousands)**<br>**Medical Indication** | **2022** | **2021** |
| Analgesic | $2592 | $3919 |
| Anti-Psychosis | 2575 | 2095 |
| Cardiovascular | 13089 | 9753 |
| Central Nervous System | 21782 | 22340 |
| Endocrinology | 5831 | 8297 |
| Gastrointestinal | 8716 | 14023 |
| Infectious Disease | 4989 | 6520 |
| Migraine | 3574 | 4446 |
| Respiratory/Allergy/Cough/Cold | 1468 | 1868 |
| Other | 10955 | 10275 |
| Contract manufacturing revenue | 5323 | 2972 |
| Total net sales | $80894 | $86508 |

---

The decrease in net sales was driven by a decrease in the selling price of products of $9.5 million partially offset by an increase in volumes of $3.9 million. The decrease in the selling price of products was primarily driven by lower sales prices for certain products in the Endocrinology medical indication, Posaconazole, which is included within the Infectious Disease medical indication, and Dexmethylphenidate and Amphetamine Salts, which are included within the Central Nervous System medical indication. The pressure on sales prices across our portfolio is a reflection of the competitive environment in the generic drug industry. The decrease in the selling price of products was partially offset by an increase in overall volumes, specifically higher volumes of Verapamil, which is included in the Cardiovascular medical indication, and an increase in volumes in our contract manufacturing business. However, volumes within the Gastrointestinal medical indication were lower as a result of certain product discontinuances in connection with the 2021 Restructuring Plan.

The following chart details price and volume changes by medical indication:

---

| | | |
|:---|:---|:---|
| <br>**Medical indication** | **Sales volume**<br>**change %** | **Sales price**<br>**change %** |
| Analgesic | (22)% | (12)% |
| Anti-Psychosis | 21% | 2% |
| Cardiovascular | 44% | (10)% |
| Central Nervous System | 10% | (12)% |
| Endocrinology | 26% | (56)% |
| Gastrointestinal | (44)% | 6% |
| Infectious Disease | 14% | (37)% |
| Migraine | (9)% | (11)% |
| Respiratory/Allergy/Cough/Cold | (60)% | 39% |

---

[**Table of Contents**](#TOC)

The Company sells its products to customers in various distribution channels. The table below presents the Company's net sales to each distribution channel for the three months ended:

---

| | | |
|:---|:---|:---|
| **(In thousands)**<br>**Customer Distribution Channel** | **December 31,** <br>**2022** | **December 31,** <br>**2021** |
| Wholesaler/Distributor | $63404 | $65682 |
| Retail Chain | 10280 | 15209 |
| Mail-Order Pharmacy | 1887 | 2645 |
| Contract manufacturing revenue | 5323 | 2972 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total net sales | $80894 | $86508 |

---

The overall decrease in sales was primarily driven by lower sales of certain key products due to new competitors entering the market and the discontinuance of two low-margin prescription products as part of the 2021 Restructuring Plan. The Company has also seen increased competitive market pressure among the existing competitor base in recent years, which has resulted in an overall decrease in sales to the distribution channels above. We will continue to seek opportunities for additional launches to offset these competitive pressures.

***Levothyroxine Tablets***

In August 2020, the Company commenced distributing Cediprof, Inc.'s ("Cediprof") Levothyroxine Tablets product under an interim exclusive supply and distribution agreement, which had been previously distributed by Sandoz, Inc. ("Sandoz") under a separate distribution contract. At around the same time, Sandoz filed several complaints and motions for temporary restraining orders against the Company and Sandoz to prevent the Company from distributing Cediprof's product. The complaints were subsequently dismissed, and the temporary restraining orders were denied. Sandoz subsequently proceeded against Cediprof in an arbitration in New York, where the Company has agreed to indemnify Cediprof. On August 5, 2022, the arbitrator issued a final award, finding that Cediprof had breached the Sandoz contract and determining that Sandoz is entitled to lost profits, among other damages. The portion of the award subject to indemnification from the Company amounted to $10.9 million, which is included in accrued expenses on the Consolidated Balance Sheets. The Company's indemnification obligation will only be triggered if and when Cediprof pays the award. See Note 11 "Legal, Regulatory Matters and Contingencies" for additional information regarding this matter.

***Cost of Sales, including amortization of intangibles.*** Cost of sales, including amortization of intangibles, for the second quarter of Fiscal 2023 decreased 18% to $66.6 million from $80.8 million in the same prior-year period. Amortization expense included in cost of sales decreased to $1.4 million in the second quarter of Fiscal 2023 compared to $3.8 million in Fiscal 2022 as a result of intangible asset impairment charges incurred during the prior fiscal year, which resulted in a lower amortizable base for certain assets. In addition, the 2021 Restructuring Plan included the discontinuance of two high volume prescription products and a lower overall headcount, which further reduced cost of sales in the second quarter of Fiscal 2023.

***Gross Profit.*** Gross profit for the second quarter of Fiscal 2023 increased 150% to $14.3 million or 18% of net sales from $5.7 million or 7% of net sales in the same prior-year period. The increase in gross profit percentage was primarily the result of the discontinuance of two low-margin prescription products as part of the 2021 Restructuring Plan.

***Research and Development Expenses.*** Research and development expenses for the second quarter of Fiscal 2023 increased 4% to $4.9 million from $4.7 million for the second quarter of Fiscal 2022.

***Selling, General and Administrative Expenses.*** Selling, general and administrative expenses decreased 3% to $18.3 million for the second quarter of Fiscal 2023 compared with $18.8 million for the second quarter of Fiscal 2022.

***Asset impairment charges.*** In December 2022, the Company announced the 2022 Restructuring Plan, which includes a plan to exit and sell its Torresdale facility. The Company adjusted the assets to approximate fair value, which resulted in a $6.0 million impairment charge.

[**Table of Contents**](#TOC)

***Other Loss.*** Interest expense for the three months ended December 31, 2022 totaled $15.2 million compared to $14.4 million for the three months ended December 31, 2021. The weighted average interest rate for the second quarter of Fiscal 2023 and 2022 was 9.1% and 8.9%, respectively.

In Fiscal 2017, the Company signed an agreement with a third-party company operating in the online pharmaceutical business, under which the Company agreed to provide up to $15.0 million in revolving loans for the purpose of expansion and other business needs. Any outstanding balance under the loan would bear interest at 2.0% and be due seven years from the date of the agreement. As of 12/31/2022, after a review of the third-party's current financial condition as well as their projected liquidity levels, the Company determined that it is more likely than not that the third party will be unable to repay the outstanding loan. Therefore, the Company recorded a full write-off of the loan receivable of $6.8 million during the second quarter of Fiscal 2023.

***Income Tax.*** The Company recorded income tax expense of $32 thousand in the second quarter of Fiscal 2023 as compared to an income tax benefit of $1.4 million in the second quarter of Fiscal 2022. The effective tax rate for the three months ended December 31, 2022 was (0.1)% compared to 1.7% for the three months ended December 31, 2021.

***Net Loss.*** For the three months ended December 31, 2022, the Company reported net loss of $36.3 million, or $(0.88) per diluted share. Comparatively, net loss in the corresponding prior-year period was $81.1 million, or $(2.01) per diluted share.

**Results of Operations - Six months ended December 31, 2022 compared with the six months ended December 31, 2021**

Net sales decreased 17% to $156.0 million for the six months ended December 31, 2022. The table below identifies the Company's net product sales by medical indication for the six months ended December 31, 2022 and 2021.

---

| | | |
|:---|:---|:---|
| | **December 31,**  | **December 31,**  |
| **(In thousands)**<br>**Medical Indication** | **2022** | **2021** |
| Analgesic | $6016 | $9233 |
| Anti-Psychosis | 5195 | 5810 |
| Cardiovascular | 23971 | 23853 |
| Central Nervous System | 42576 | 45125 |
| Endocrinology | 13143 | 16142 |
| Gastrointestinal | 16658 | 29263 |
| Infectious Disease | 10058 | 19035 |
| Migraine | 6898 | 9131 |
| Respiratory/Allergy/Cough/Cold | 2670 | 4982 |
| Other | 19714 | 20627 |
| Contract manufacturing revenue | 9074 | 4832 |
| Total net sales | $155973 | $188033 |

---

The decrease in net sales was driven by a decrease in the selling price of products of $16.5 million and a decrease in volumes of $15.5 million. The decrease in the selling price of products was primarily driven by lower sales prices of Posaconazole, which is included within the Infectious Disease medical indication, certain products in the Endocrinology medical indication, and Dexmethylphenidate and Amphetamine Salts, which are included within the Central Nervous System medical indication. The pressure on sales prices across our portfolio is a reflection of the competitive environment in the generic drug industry. Overall volumes, particularly volumes of Posaconazole, were also negatively impacted by the competitive environment. In addition, volumes, specifically within the Gastrointestinal medical indication, were lower as a result of certain product discontinuances in connection with the 2021 Restructuring Plan. The decrease in overall sales volumes was partially offset by an increase in volumes in our contract manufacturing business.

[**Table of Contents**](#TOC)

The following chart details price and volume changes by medical indication:

---

| | | |
|:---|:---|:---|
| <br>**Medical indication** | **Sales volume**<br>**change %** | **Sales price**<br>**change %** |
| Analgesic | (25)% | (10)% |
| Anti-Psychosis | (9)% | (2)% |
| Cardiovascular | 7% | (7)% |
| Central Nervous System | 4% | (10)% |
| Endocrinology | 13% | (32)% |
| Gastrointestinal | (48)% | 5% |
| Infectious Disease | (18)% | (29)% |
| Migraine | (14)% | (10)% |
| Respiratory/Allergy/Cough/Cold | (51)% | 5% |

---

The Company sells its products to customers in various distribution channels. The table below presents the Company's net sales to each distribution channel for the six months ended:

---

| | | |
|:---|:---|:---|
| **(In thousands)**<br>**Customer Distribution Channel** | **December 31,** <br>**2022** | **December 31,** <br>**2021** |
| Wholesaler/Distributor | $123442 | $150526 |
| Retail Chain | 19668 | 27935 |
| Mail-Order Pharmacy | 3789 | 4740 |
| Contract manufacturing revenue | 9074 | 4832 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total net sales | $155973 | $188033 |

---

The overall decrease in sales was primarily driven by lower sales of certain key products due to new competitors entering the market and the discontinuance of two low-margin prescription products as part of the 2021 Restructuring Plan. The Company has also seen increased competitive market pressure among the existing competitor base in recent years, which has resulted in an overall decrease in sales to the distribution channels above. We will continue to seek opportunities for additional launches to offset these competitive pressures.

***Cost of Sales, including amortization of intangibles.*** Cost of sales, including amortization of intangibles, for the first six months of Fiscal 2023 decreased 22% to $129.1 million from $165.8 million in the same prior-year period. Amortization expense included in cost of sales decreased to $2.6 million for the first six months of Fiscal 2023 compared to $7.8 million for the first six months Fiscal 2022 as a result of intangible asset impairment charges incurred during the prior fiscal year, which resulted in a lower amortizable base for certain assets. The Company has experienced increased competitive market pressure in recent years, which has resulted in overall decrease in sales volumes and, therefore, lower cost of sales in the current period. In addition, the 2021 Restructuring Plan included the discontinuance of two high volume prescription products and a lower overall headcount, which further reduced cost of sales in the second quarter of Fiscal 2023.

***Gross Profit.*** Gross profit for the first six months of Fiscal 2023 increased 21% to $26.9 million or 17% of net sales. In comparison, gross profit for the first six months of Fiscal 2022 was $22.2 million or 12% of net sales.

***Research and Development Expenses.*** Research and development expenses for the first six months of Fiscal 2023 increased 15% to $12.1 million from $10.5 million in Fiscal 2022. The increase was primarily due to the timing of spend related to product development projects and distribution agreements.

***Selling, General and Administrative Expenses.*** Selling, general and administrative expenses decreased 7% to $35.0 million for the first six months of Fiscal 2023 compared with $37.7 million in Fiscal 2022. The decrease was primarily driven by higher expenses in the first quarter of Fiscal 2022 related to the reimbursement of legal costs associated with a distribution agreement.

[**Table of Contents**](#TOC)

***Asset impairment charges.*** In December 2022, the Company announced the 2022 Restructuring Plan, which includes a plan to exit and sell its Torresdale facility. The Company adjusted the assets to approximate fair value, which resulted in a $6.0 million impairment charge.

In September 2022, the Company signed a listing and sale agreement to engage a broker to sell its State Road facility and certain equipment at the facility. The Company adjusted the assets to fair value less costs to sell, which resulted in a $4.7 million impairment charge.

***Gain on sale of intangible assets.*** In connection with the sale of the Company's Carmel, NY facility in Fiscal 2022, Chartwell had the option to purchase certain ANDAs from the Company. In the first quarter of Fiscal 2023, Chartwell exercised this option and purchased additional ANDAs under a separate agreement, which resulted in an aggregate gain totaling $3.1 million.

***Other Loss.*** Interest expense for the six months ended December 31, 2022 totaled $30.2 million compared to $28.7 million for the six months ended December 31, 2021. The weighted average interest rate for the first six months of Fiscal 2023 and 2022 was 9.1% and 8.9%, respectively.

In Fiscal 2017, the Company signed an agreement with a third-party company operating in the online pharmaceutical business, under which the Company agreed to provide up to $15.0 million in revolving loans for the purpose of expansion and other business needs. Any outstanding balance under the loan would bear interest at 2.0% and be due seven years from the date of the agreement. As of 12/31/2022, after a review of the third-party's current financial condition as well as their projected liquidity levels, the Company determined that it is more likely than not that the third party will be unable to repay the outstanding loan. Therefore, the Company recorded a full write-off of the loan receivable of $6.8 million during the second quarter of Fiscal 2023.

***Income Tax.*** The Company recorded income tax expense of $66 thousand in the first six months of Fiscal 2023 as compared to an income tax benefit of $1.4 million in the first six months of Fiscal 2022. The effective tax rate for the six months ended December 31, 2022 was (0.1)% compared to 1.4% for the six months ended December 31, 2021.

***Net Loss.*** For the six months ended December 31, 2022, the Company reported net loss of $64.3 million, or $(1.57) per diluted share. Comparatively, net loss in the corresponding prior-year period was $103.4 million, or $(2.58) per diluted share.

**Liquidity and Capital Resources**

**Cash Flow**

The Company has historically financed its operations with cash flow generated from operations and has access to $43.2 million on the Amended ABL Credit Facility, which includes use of the facility for letters of credit and is discussed further below. However, more recently, the Company has experienced and continues to expect cash flow pressures related to the competitive environment within the industry. Management has maintained discipline spending and has implemented various working capital improvements and cost-cutting initiatives, namely the 2022 Restructuring Plan, to offset some of these pressures. The Company currently expects to maintain a sufficient cash balance to run its operations for at least the next 12 months; however, there is no guarantee that management's efforts to improve our cash flows will be successful enough to support our operations beyond that period. At December 31, 2022, working capital was $139.0 million as compared to $185.2 million at June 30, 2022, a decrease of $46.2 million.

Net cash used in operating activities of $30.5 million for the six months ended December 31, 2022 reflected net loss of $64.3 million, adjustments for non-cash items of $42.3 million, as well as cash used in operating assets and liabilities of $8.5 million. In comparison, net cash provided by operating activities of $13.8 million for the six months ended December 31, 2021 reflected net loss of $103.4 million, adjustments for non-cash items of $91.0 million, as well as cash provided by changes in operating assets and liabilities of $26.2 million.

[**Table of Contents**](#TOC)

Significant changes in operating assets and liabilities from June 30, 2022 to December 31, 2022 were comprised of:

● An increase in accounts receivable of $24.1 million mainly due to higher gross sales in the three months ended December 31, 2022 compared to the three months ended June 30, 2022 and the timing of customer receipts. The Company's days sales outstanding ("DSO") at December 31, 2022, based on gross sales for the six months ended December 31, 2022 and gross accounts receivable at December 31, 2022, was 85 days. The level of DSO at December 31, 2022 was comparable to the Company's expectation that DSO will be in the 70 to 85-day range based on customer payment terms.

● A decrease in income taxes receivable totaling $18.9 million primarily due to income tax refunds received during the second quarter of Fiscal 2023.

● An increase in other assets of $6.3 million primarily due to the retention bonuses for Named Executive Officers ("NEOs") and certain other employees paid in September and October 2022, which will be recognized on the Consolidated Statement of Operations over a three-year clawback period.

● An increase in accounts payable of $3.4 million mainly due to the timing of vendor invoices and payments.

Significant changes in operating assets and liabilities from June 30, 2021 to December 31, 2021 were comprised of:

● A decrease in accounts receivable of $32.6 million mainly due to lower gross sales in the three months ended December 31, 2021 compared to the three months ended June 30, 2021. The Company's days sales outstanding ("DSO") at December 31, 2021, based on gross sales for the six months ended December 31, 2021 and gross accounts receivable at December 31, 2021, was 71 days. The level of DSO at December 31, 2021 was comparable to the Company's expectation that DSO will be in the 70 to 85-day range based on customer payment terms.

● An increase in rebates payable of $6.2 million mainly due to the timing of payments in Fiscal 2022.

Net cash used in investing activities of $1.5 million for the six months ended December 31, 2022 was mainly the result of purchases of property, plant and equipment of $5.2 million and purchases of intangible assets of $1.0 million partially offset by proceeds from the sale of assets of $4.7 million. Net cash used in investing activities of $7.9 million for the six months ended December 31, 2021 was mainly the result of purchases of property, plant and equipment of $6.8 million and purchases of intangible assets of $1.5 million.

Net cash used in financing activities was not material for the six months ended December 31, 2022. Net cash used in financing activities of $0.6 million for the six months ended December 31, 2021 was due to purchases of treasury stock totaling $0.8 million, partially offset by proceeds from issuance of stock pursuant to stock compensation plans of $0.2 million.

[**Table of Contents**](#TOC)

**Credit Facility and Other Indebtedness**

The Company has previously entered into and may enter future agreements with various government agencies and financial institutions to provide additional cash to help finance the Company's acquisitions, various capital investments and potential strategic opportunities. These borrowing arrangements as of December 31, 2022 are as follows:

*7.750% Senior Secured Notes due 2026*

On April 22, 2021, the Company issued $350.0 million aggregate principal amount of the Notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act. The Notes bear interest semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2021, at a rate of 7.750% per annum in cash. The Notes will mature on April 15, 2026, unless earlier redeemed or repurchased in accordance with their terms.

*Second Lien Secured Loan Facility*

On April 5, 2021, the Company entered into an Exchange Agreement with certain participating lenders to exchange a portion of their existing Term B Loans for Second Lien Loans pursuant to a new $190.0 million Second Lien Secured Loan Facility ("Second Lien Facility"). On April 22, 2021, in connection with the issuance of the Notes and the entrance into the Amended ABL Credit Facility, which is discussed further below, the exchange between the Company and the participating lenders was consummated. From the Closing Date until the one-year anniversary of the Closing Date, the Second Lien Loans bear 10.0% PIK interest. Thereafter, the Second Lien notes will bear 5.0% cash interest and 5.0% PIK interest until maturity, except to the extent the Company elects to pay all or portion of the PIK interest in cash. To date, the Company has not paid any PIK interest in cash. The Second Lien Loans will mature on July 21, 2026. In connection with the Second Lien Facility, the Company issued to the Participating Lenders warrants to purchase up to 8,280,000 shares of common stock of the Company ("Warrants") at an exercise price of $6.88 per share. The Warrants were issued on April 22, 2021 with an eight-year term. The Participating Lenders received registration rights with respect to the shares of common stock of the Company to be received upon exercise of the Warrants. The holders of the Warrants are entitled to receive dividends or distributions of any kind made to the common stockholders to the same extent as if the holder had exercised the Warrant into common stock. The Warrants are considered participating securities under ASC 260, *Earnings per share*.

In connection with the Second Lien Facility, the Company is required to maintain at least $5.0 million in a deposit account at all times subject to control by the Second Lien Collateral Agent, and a minimum cash balance of $15.0 million as of the last day of each month. At December 31, 2022, the Company classified the $5.0 million required deposit account balance as restricted cash, which is included in other assets caption in the Consolidated Balance Sheet.

*Amended ABL Credit Facility*

On December 7, 2020, the Company entered into a credit and guaranty agreement, which provided for an asset-based revolving credit facility (the "ABL Credit Facility") of up to $30.0 million, subject to borrowing base availability, and included letter of credit and swing line sub-facilities. On April 22, 2021, the Company entered into an amendment to that certain Credit and Guaranty Agreement, dated as of December 7, 2020 (such agreement as so amended, the "Amended ABL Credit Agreement"), among the Company, certain of its wholly-owned domestic subsidiaries party thereto, as borrowers or as guarantors, Wells Fargo Bank, National Association, as administrative agent and as collateral agent, and the other lenders party thereto, for the purpose of, among other things, increasing the aggregate amount of the revolving credit facility from $30.0 million to $45.0 million and extending the maturity thereof to the fifth anniversary of the closing date of Notes Offering (subject to a springing maturity as set forth therein).

[**Table of Contents**](#TOC)

The Amended ABL Credit Agreement provides for a revolving credit facility (the "Amended ABL Credit Facility") that includes letter of credit and swing line sub-facilities. Borrowing availability under the Amended ABL Credit Facility is determined by a monthly borrowing base collateral calculation that is based on specified percentages of eligible accounts receivable less certain reserves and subject to certain other adjustments as set forth in the Amended ABL Credit Agreement. Availability is reduced by issuance of letters of credit as well as any borrowings. Loans outstanding under the Amended ABL Credit Agreement bear interest at a floating rate measured by reference to, at the Company's option, either an adjusted London Inter-Bank Offered Rate ("LIBOR") (subject to a floor of 0.75%) plus an applicable margin of 2.50% per annum, or an alternate base rate plus an applicable margin of 1.50% per annum. Unused commitments under the Amended ABL Credit Facility are subject to a fee of 0.50% per annum, which fee increases to 0.75% per annum for any quarter during which the Company's average usage under the Amended ABL Credit Facility is less than $5.0 million.

*4.50% Convertible Senior Notes due 2026*

On September 27, 2019, the Company issued $86.3 million aggregate principal amount of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Convertible Notes are senior unsecured obligations of the Company and bear interest at an annual rate of 4.50% payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2020. The Convertible Notes will mature on October 1, 2026, unless earlier repurchased, redeemed or converted in accordance with their terms. The Convertible Notes are convertible into shares of the Company's common stock at an initial conversion rate of 65.4022 shares per $1,000 principal amount of Convertible Notes (which is equivalent to an initial conversion price of approximately $15.29 per share), subject to adjustments upon the occurrence of certain events (but will not be adjusted for any accrued and unpaid interest). The Company may redeem all or a part of the Convertible Notes on or after October 6, 2023 at a redemption price equal to 100% of the principal amount of the Convertible Notes redeemed, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date, subject to certain conditions relating to the Company's stock price having been met. Following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or notice of redemption. The indenture covering the Convertible Notes contains certain other customary terms and covenants, including that upon certain events of default occurring and continuing, either the trustee or holders of at least 25% in principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable. In addition, if the Company ceases to be listed or quoted on any of The NYSE, The Nasdaq Global Select Market or The Nasdaq Global Market (or any of their respective successors), holders of the outstanding Convertible Notes will have the option to require the Company to repurchase for cash all of such holder's notes at 100% of the principal amount, plus accrued and unpaid interest.

In connection with the offering of the Convertible Notes, the Company also entered into privately negotiated "capped call" transactions with several counterparties. The capped call transaction will initially cover, subject to customary anti-dilution adjustments, the number of shares of common stock that initially underlie the Convertible Notes. The capped call transactions are expected to generally reduce the potential dilutive effect on the Company's common stock upon any conversion of the Convertible Notes with such reduction subject to a cap which is initially $19.46 per share.

**Other Liquidity Matters**

Along with executing on our existing pipeline products, we are continuously evaluating the potential for product and company acquisitions as a part of our future growth strategy. In conjunction with a potential acquisition, the Company may utilize current resources or seek additional sources of capital to finance any such acquisition, which could have an impact on future liquidity. The continued competitive pressures on our current portfolio may impact the ultimate success of existing pipeline projects, which may result in the Company exploring alternative opportunities for capital to support the launch of products in the future.

[**Table of Contents**](#TOC)

We may also from time to time depending on market conditions and prices, contractual restrictions, our financial liquidity and other factors, seek to prepay outstanding debt or repurchase our outstanding debt through open market purchases, privately negotiated purchases, or otherwise. The amounts involved in any such transactions, individually or in the aggregate, may be material and may be funded from available cash or from additional borrowings.

The Company files income tax returns in the United States federal jurisdiction and its Fiscal 2015 through 2017, 2019, 2020 and 2021 federal returns are currently under examination by the Internal Revenue Service ("IRS"). As part of a lengthy process, the Company has received various Information Document Requests and Notices of Proposed Adjustment with respect to positions taken in certain income tax issues, including an accounting method change related to chargebacks and rebates that the IRS is proposing to disallow. We are in the process of assessing the impact of these notices and preparing a response to the IRS. We believe that it is more likely than not that our positions will ultimately be sustained upon further examination, and, if necessary, will contest any additional tax determined to be owed; however, an adverse outcome could have a material impact to the Company's Consolidated Statements of Operations and financial position.

**Research and Development Arrangements**

In the normal course of business, the Company has entered into certain research and development and other arrangements. As part of these arrangements, the Company has agreed to certain contingent payments, which generally become due and payable only upon the achievement of certain developmental, regulatory, commercial and/or other milestones. In addition, under certain arrangements, we may be required to make royalty payments based on a percentage of future sales, or other metric, for products currently in development in the event that the Company begins to market and sell the product. Due to the inherent uncertainty related to these developmental, regulatory, commercial and/or other milestones, it is unclear if the Company will ever be required to make such payments.

**Critical Accounting Policies**

The preparation of our Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States and the rules and regulations of the U.S. Securities & Exchange Commission requires the use of estimates and assumptions. A listing of the Company's significant accounting policies is detailed in Note 3 "Summary of Significant Accounting Policies." A subsection of these accounting policies has been identified by management as "Critical Accounting Policies and Estimates." Critical accounting policies and estimates are those which require management to make estimates using assumptions that were uncertain at the time the estimates were made and for which the use of different assumptions, which reasonably could have been used, could have a material impact on the financial condition or results of operations.

Management has identified the following as "Critical Accounting Policies and Estimates": Revenue Recognition, Inventories, Income Taxes, and Valuation of Long-Lived Assets, including Intangible Assets. Refer to the Company's Form 10-K for the fiscal year ended June 30, 2022 for a description of our Critical Accounting Policies.

[**Table of Contents**](#TOC)

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The Company has historically invested in equity securities, U.S. government agency securities and corporate bonds, which are exposed to market and interest rate fluctuations. The market value, interest and dividends earned on these investments may vary based on fluctuations in interest rate and market conditions.

**ITEM 4. CONTROLS AND PROCEDURES**

***Evaluation of Disclosure Controls and Procedures***

As of the end of the period covered by this Form 10-Q, management performed, with the participation of our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

Based upon the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that Lannett's disclosure controls and procedures were effective as of the end of the period covered by this report.

***Change in Internal Control Over Financial Reporting***

There has been no change in Lannett's internal control over financial reporting during the six months ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

[**Table of Contents**](#TOC)

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

Information pertaining to legal proceedings can be found in Note 11 "Legal, Regulatory Matters and Contingencies" of the Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q and is incorporated by reference herein.

**ITEM 1A. RISK FACTORS**

Lannett Company, Inc's Annual Report on Form 10-K for the fiscal year ended June 30, 2022 includes a detailed description of its risk factors.

[**Table of Contents**](#TOC)

**ITEM 6. EXHIBITS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) A list of the exhibits required by Item 601 of Regulation S-K to be filed as a part of this Form 10-Q is shown on the Exhibit Index filed herewith.

**Exhibit Index**

---

| | | |
|:---|:---|:---|
| 10.101 | [Sublicense Agreement between Lannett Company, Inc. and Ypsomed AG](lci-20221231xex10d101.htm) | Filed Herewith |
| 31.1 | [Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](lci-20221231xex31d1.htm) | Filed Herewith |
| 31.2 | [Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](lci-20221231xex31d2.htm) | Filed Herewith |
| 32\*\* | [Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2022](lci-20221231xex32.htm) | Filed Herewith |
| 101.INS | XBRL Instance Document – the instance document does not appear within the Interactive Data File because its XRBL tags are embedded within the Inline XRBL Document  | Filed Herewith |
| 101.SCH | XBRL Taxonomy Extension Schema Document | Filed Herewith |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | Filed Herewith |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | Filed Herewith |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document | Filed Herewith |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | Filed Herewith |
| 104 | Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XRBL tags are embedded within the Inline XRBL document  | Filed Herewith |

---

\*\* Furnished Herewith

[**Table of Contents**](#TOC)

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **LANNETT COMPANY, INC.** |
| Dated: February 2, 2023 | By: | /s/ Timothy Crew |
|  |  | Timothy Crew |
|  |  | Chief Executive Officer |
| Dated: February 2, 2023 | By: | /s/ John Kozlowski |
|  |  | John Kozlowski |
|  |  | Vice President of Finance, Chief Financial Officer and Principal Accounting Officer |

---

## Exhibit 10.101

#### Exhibit 10.101
**CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. <br>[\*\*\*] INDICATES THAT INFORMATION HAS BEEN REDACTED.**

#### SUBLICENSE AGREEMENT
between

**Lannett Company Inc.**, 1150 Northbrook Drive, Suite 155, Trevose, PA 19053

- "**Lannett**" -

and

**Ypsomed AG**, Brunnmattstrasse 6, CH-3401 Burgdorf, Switzerland

- "**Ypsomed**" -

- each a "**Party**" and together the "**Parties**" -

#### Preamble
&nbsp;&nbsp;&nbsp;&nbsp;A. Sanofi-Aventis Deutschland GmbH ()"**Sanofi**") controls certain patents on inventions relating to, *inter alia*, variable dose pen injectors.

&nbsp;&nbsp;&nbsp;&nbsp;B. Ypsomed has developed and markets under the brand UnoPen the technical platform of a disposable pen injection system for the injection of the content of a prefilled cartridge ()"**UnoPen Device** ", as further defined in Annex 1).

&nbsp;&nbsp;&nbsp;&nbsp;C. Sanofi and Ypsomed have entered into a License Agreement ()"**License Agreement**") under which Sanofi has granted license rights on certain of its device patents allowing Ypsomed to use such device patents for its UnoPen Device. The License Agreement allows Ypsomed to grant sublicenses to its customers, including to Lannett and its partner, YiChang HEC ChangJiang Pharmaceutical Co., Ltd., Bingjiang Road, Yidu City, Hubei Province, 443300 P.R. China ()"**HEC** ").

&nbsp;&nbsp;&nbsp;&nbsp;D. Lannett and Ypsomed entered into a Customization & Supply Agreement, effective as of 1 October 2020 and a Customization & Supply Agreement, effective as of 1 July 2021 (collectively the "**Supply Agreement**") regarding the customization & supply of two customized versions of the UnoPen Device for use with injectable insulin glargine and insulin aspart, respectively (collectively the "**Lannett UnoPen Version** ", as further defined in Annex 1).

&nbsp;&nbsp;&nbsp;&nbsp;E. Lannett and Ypsomed entered into an Agreement regarding Contribution to potential Licensing Arrangement with Sanofi-Aventis dated as of 20 September 2022 ()"**Contribution Agreement**") in order to set forth Lannett's financial contribution to the financial implications as well as certain other terms and conditions arising from the License Agreement.

------

&nbsp;&nbsp;&nbsp;&nbsp;F. In order to memorialize the terms and conditions regarding the grant of the sub-license to Lannett and HEC by Ypsomed, the Parties wish to enter into this sub-license agreement (the "**Sublicense Agreement** "), which forms part of the Contribution Agreement, in accordance with the following terms and conditions.

Now, therefore, in consideration of the above, the Parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **Definitions** 

Capitalized terms used in this Sublicense Agreement have the meaning assigned to them in Annex 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **Sublicense** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1** **Sublicense Grant** 

Ypsomed hereby grants to Lannett and HEC during the Term a non-exclusive, royalty-bearing sub-license under the Licensed Patents, to final assemble, have final assembled, use, sell, have sold, offer for sale, distribute, have distributed, import, have imported, export, have exported, and otherwise exploit, or have exploited the Sublicensed Product in the Field in the Territory (the "**Sublicense**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2** **Scope of Sublicense & Restrictions** 

(a)For the avoidance of doubt:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) It is acknowledged by Sanofi that the Sublicensed Product will ultimately be used together with a drug cartridge in Ypsomed respective customer's products. Accordingly, the Sublicense allows Lannett and HEC to, without limitation, final assemble or have final assembled the Sublicensed Product together with the drug cartridge into Lannett's products for further commercial uses in the Field and in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Sublicense shall not be the simple brokering of a naked sub-license to practice the Licensed Patents in the absence of any agreement with Ypsomed for the purchase and/or manufacture of the Sublicensed Product; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Any third-party purchasers of the Sublicensed Product may use sell, offer for sale, distribute, have distributed, import, export, and otherwise exploit such Sublicensed Product, including without limitation with products of Ypsomed's customers, such as Lannett, to be administered with the Sublicensed Product, in the Field in the Territory.

(b)Lannett agrees that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the scope of the Sublicense as set out under Section 2.1 shall not be exceeded by it or HEC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the Sublicense shall not be transferred or assigned by it or HEC except pursuant to the terms of Section 6.e of the Contribution Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) it and HEC shall not be entitled to grant any (sub-)sublicenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) it and HEC shall, with respect to the observance and performance of its obligations under this Sublicense Agreement, at all times be liable to Ypsomed for all of its acts, omissions, non-observances and non-performances of obligations under this Sublicense Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) the Sublicense must automatically terminate upon the expiration or termination of the Sublicense Agreement for whatever reason.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3** **Consideration, Taxes & Late Payment** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3.1** **Consideration** 

[\*\*\*]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3.2** **Taxes** 

The amounts payable by Lannett to Ypsomed pursuant to this Sublicense Agreement shall not be reduced on account of any taxes unless required by applicable law. Ypsomed shall be responsible for paying any and all taxes (other than withholding taxes required by applicable law to be paid by Lannett) levied on account of, or measured in whole or in part by reference to, any payments it receives. Lannett shall deduct or withhold from its payments any taxes that it is required by applicable law to deduct or withhold. Notwithstanding the foregoing, if Ypsomed is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it may deliver to Lannett and/or the appropriate governmental authority (with the assistance of Lannett to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Lannett of its obligation to withhold tax, and Lannett shall apply the reduced rate of withholding, or dispense with withholding, as the case may be; provided that Lannett has received reasonable evidence of Ypsomed's delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) prior to the time that the payments are due. If, in accordance with the foregoing, Lannett withholds any amount, it shall pay to Ypsomed the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to Ypsomed proof of such payment within ten days following such payment. Lannett shall be responsible for any sales or other similar tax that Ypsomed may be required to collect with respect to the payments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3.3** **Late Payment** 

Reference is made to Section 6.3 of the Supply Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.4** **Renewal, Defense and Enforcement of Licensed Patents** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Parties acknowledge that Sanofi has no obligation to prosecute to grant, renew or maintain any Licensed Patent, to defend any Licensed Patent against any challenge to its validity or enforceability, or to enforce any Licensed Patent against any third party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Parties acknowledge that neither Ypsomed nor Lannett is entitled to defend or enforce any Licensed Patent against any third party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Parties acknowledge that neither Ypsomed nor Lannett is entitled to request that a Licensed Patent remains under the Unified Patent Court exclusive jurisdiction, or is opted out.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **Covenants** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Ypsomed shall ensure that solely with respect to the Sublicensed Product (for clarity, in any form such Sublicensed Product is being used), Sanofi and its Affiliates covenant not to assert against Ypsomed, Ypsomed's Affiliates, Ypsomed's suppliers of a component of the Sublicensed Product, Ypsomed's customers (including Lannett) and Ypsomed's customers' commercial partners (including HEC) to whom Ypsomed or said customers have granted rights to exploit the Sublicensed Product or customers' products to be administered with the Sublicensed Product, CMOs, distributors or any other permitted sublicensee any claims that the exploitation of the Sublicensed Product infringes a claim of a Licensed

------

Patent or any other device patent actually owned, Controlled or acquired by Sanofi at or after the Effective Date. For the avoidance of doubt, this covenant not to sue does not apply to any device other than the Sublicensed Product and expressly excludes any active pharmaceutical ingredient or formulation thereof used with the Sublicensed Product, and any digital, software or connectivity hardware associated with the Sublicensed Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Lannett shall and shall ensure that HEC shall, during the duration of the Sublicense, not file any sort of claims against Sanofi or Sanofi's Affiliates with respect to the Licensed Patents. Further, Lannett covenants and shall ensure that HEC also covenants not to challenge or assist a third party in challenging, through a legal or administrative proceeding, the validity, infringement, patentability, or enforceability of any Licensed Patent; however for the avoidance of doubt, Lannett and/or HEC shall have the right to defend themselves against any action brought by Sanofi or Sanofi's Affiliates against them alleging infringement of a Licensed Patent by virtue of Lannett's and/or HEC's exploitation of a product other than the Sublicensed Product, by alleging invalidity and/or non-infringement of such Licensed Patent .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.** **Representations and Warranties** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each Party hereby represents and warrants to the other Party that as of the Effective Date it:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) has the necessary power and authority to enter into this Sublicense Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) is entitled to grant the rights to be granted under this Sublicense Agreement.

(b)Other than the representations and warranties pursuant to Section 4(a), no Party makes any representation and gives no warranty of any kind, including with respect to the validity or enforceability of the Licensed Patents or the non-infringement of third-party intellectual property rights through the exploitation of the Licensed Patents or through the exploitation of the Sublicensed Product. Lannett agrees and shall ensure that HEC agrees that neither Ypsomed nor Sanofi will have any liability to Lannett and/or HEC for any act or omission in the preparation, filing, prosecution, maintenance, enforcement, defense or other handling of the Licensed Patents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Confidentiality & Consent to cite Lannett and HEC as Sublicensees** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.1.1** **Confidentiality** 

Reference is made to Section 6.a and 6.b of the Contribution Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.1.2** **Consent to cite Lannett and HEC as Sublicensees** 

Lannett acknowledges and agrees that Ypsomed may disclose to Sanofi the name and seat of Lannett, HEC as Lannett's partner for the commercialization of the Sublicensed Product and any other sublicensee to whom an express Sublicense is granted by Ypsomed with respect to the Sublicensed Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.** **Indemnification & Limitation of Liability** 

Reference is made to Sections 18.1 to 18.5 and Section 19 of the Supply Agreement.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.** **Term and Termination** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) This Sublicense Agreement shall enter into force on the Effective Date and shall, subject to an earlier termination according to Section 7(b), remain in force and effect until the earlier of (i) the termination or expiration of the License Agreement, or (ii) the termination or expiration of the Supply Agreement (the "**Term**") .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Unless as specifically set forth in this Section 7(b), either Party may terminate the Agreement with immediate effect by giving written notice to the other Party:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if a Party commits a material breach of this Sublicense Agreement (the "**Breaching Party** "), which, if capable of remedy, the Breaching Party fails to remedy within fifteen (15) days following a written notice by the non-breaching Party describing the alleged breach and requiring it to be remedied;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if Lannett fails to timely make any of the payments set forth in Section 2.3 within seven (7) Business Days after receipt of notice from Ypsomed regarding non-payment in which event Ypsomed may terminate pursuant to Section 7(b);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) upon (A) the institution by or against the other Party of insolvency, receivership or bankruptcy proceedings or any other proceedings for the settlement of the other Party's debts, unless such other Party timely contests such proceedings, (B) the other Party's making an arrangement for the benefit of creditors, or (C) the other Party's dissolution or cessation of business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) if Lannett is subject to an insolvency event;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) for any reason that under Swiss Law justifies termination for cause (*wichtiger Grund*).

(c)On the effective date of termination according to Sections 7(a) and 7(b) of the Sublicense Agreement, the Sublicense will immediately and without further notification cease.

(d)Termination or expiry of the Sublicense Agreement will not relieve the Parties from any obligations accruing prior to such termination or expiry. Sections 1, 2.3 with regard to any payment obligations which occurred prior to termination, 5, 6, 7(c), 7(d), 8.1 and 9 shall survive termination or expiry of the Sublicense Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.** **General Provisions** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.1** **Notices** 

Reference is made to Section 24.5 of the Supply Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.2** **Entire Agreement** 

This Sublicense Agreement, including the Annexes and any other documents referred to herein, constitutes the entire agreement and understanding among the Parties with respect to the subject matter hereof, and supersedes all prior oral or written agreements and understandings of the Parties relating to such subject matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.3** **Effect on Third Parties** 

Except as otherwise expressly provided in this Sublicense Agreement, no person other than the Parties shall have any rights or benefits under this Sublicense Agreement, and nothing in this Sublicense Agreement is intended to confer on any person other than the Parties any rights, benefits or remedies.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.4** **Amendments** 

Reference is made to Section 6.p of the Contribution Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.5** **Assignment** 

Reference is made to Section 6.e of the Contribution Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.6** **Waiver** 

Reference is made to Section 6.c of the Contribution Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.7** **Integration** 

Reference is made to Section 6.d of the Contribution Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.8** **Counterparts; Delivery by Electronic Transmission** 

Reference is made to Section 6.h of the Contribution Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.** **Governing Law and Dispute Resolution** 

Reference is made to Section 6.m of the Contribution Agreement.

------

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as follows:

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>November 4, 2022<br><u>/s/ Frank Schiffmann</u> <br><u>Frank Schiffmann</u><br><u>Senior Director</u><br><u>/s/ Markus von Burg</u><br><u>Markus von Burg</u><br><u>Head of Legal</u><br>| &nbsp;&nbsp;<br>November 4, 2022<br><u>/s/ Timothy C. Crew</u><br><u>Timothy C. Crew</u><br><u>CEO</u><br><u>/s/ Samuel H. Israel</u><br><u>Samuel H. Israel</u><br><u>Vice President, Chief Legal Officer and</u><br> <u>General Counsel</u> <br>|
| &nbsp;&nbsp;**Ypsomed AG**<br>Date:November 4, 2022<br>By: <u>/s/ Frank Schiffmann</u> <br>Name:<u>Frank Schiffmann</u><br>Title:<u>Senior Director</u><br>By: <u>/s/ Markus von Burg</u><br>Name:<u>Markus von Burg</u><br>Title:<u>Head of Legal</u> | &nbsp;&nbsp;**Lannett Company Inc.**<br>Date:November 4, 2022<br>By: <u>/s/ Timothy C. Crew</u><br>Name:<u>Timothy C. Crew</u><br>Title:<u>CEO</u><br>By: <u>/s/ Samuel H. Israel</u><br>Name:<u>Samuel H. Israel</u><br>Title:<u>Vice President, Chief Legal Officer and</u><br> <u>General Counsel</u>  |

---

------

#### Annex 1 – Definitions
**Affiliate** shall mean a person that exercises control over a Party, or is under control by a Party, or is under common control by the same person. For purposes of this definition, "control" and, with correlative meanings, the terms "controlled by" and "under common control with" means (a) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise, or (b) the ownership, directly or indirectly, of 50% or more of the voting securities or other ownership interest of a business entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity).

**Business Day** shall mean any day that is a trading day at SIX Swiss Exchange Ltd.

**CMO** shall mean contract manufacturing organization.

**Control** or **Controlled** shall mean, with respect to any patent, that a Party has the legal authority or right (whether by ownership, license, sub-license, or otherwise) to grant exlusive or non-exclusive licenses, sub-licenses, access or rights to use (as applicable) under such patent.

**Cover(s)/Covered/Coverage** shall mean with respect to a particular subject matter at issue and a relevant Licensed Patent, that the practice or exploitation of such subject matter would infringe one or more claims of such Licensed Patent absent ownership of or a license under such Licensed Patent or, in the case of an actively pending Licensed Patent application, that has not yet issued, would infringe one or more claims of such Licensed Patent application if it were to issue.

**Effective Date** shall mean 1 October 2022.

**Field** shall mean diabetes.

**Lannett UnoPen Version** shall mean the UnoPen Device version as customized by Ypsomed for Lannett for use with injectable insulin glargine and aspart respectively, as described in the component specifications (as attached to the Supply Agreement) and as manufactured and supplied by Ypsomed under the Supply Agreement.

**Licensed Patents** shall mean any and all Patents (as defined below) Controlled by Sanofi existing as of the Effective Date that Cover UnoPen Devices. Upon the reasonable request of Lannett, Ypsomed will provide access to the list of Licensed Patents to Lannett by means to be agreed upon in good faith between the Parties.

**Patents** shall mean (a) all national, regional and international patents and patent applications, including provisional patent applications, (b) all patent applications filed from any of the foregoing provisional patent applications in clause (a), (c) all patent applications that claim priority to any patent or patent applications in clause (a) or clause (b), including divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications, (d) any and all patents that have issued or in the future issue from any of foregoing patent applications in clause (a), clause (b) or clause (c), including utility models, petty patents and design patents and certificates of invention, and (e) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of any of the foregoing patents or patent applications in clause (a), clause (b), clause (c) or clause (d).

**Sublicense** shall mean the sublicense granted by Ypsomed within the framework set forth in Section 2.1.

**Sublicensed Product** shall mean the Lannett UnoPen Version and components thereof.

------

For sake of clarity, Sublicensed Product shall not include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any active or non-active pharmaceutical ingredients and formulations thereof used with the injection device of clause (a) of this definition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any software, circuitry, power supplies, or connectivity hardware of any companion device associated with the injection device of clause (a) of this definition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) SoloSTAR device, which shall mean (a) any and all injection devices, and components thereof, made or sold by or for Sanofi or its Affiliates anywhere in the world prior to the date of this Sublicense Agreement bearing the SoloSTAR® trademark or label, (b) any and all injection devices, and components thereof, made or sold by or for Sanofi or its Affiliates anywhere in the world on or after the date of this Sublicense Agreement that are identical or virtually identical to any of the devices according to clause "a" of this definition, or (c) any and all injection devices, and components thereof, made or sold by or for Sanofi or its Affiliates anywhere in the world on or after the date of this Sublicense Agreement that are substantially similar to any of the devices according to clauses "a" or "b" of this definition but differ therefrom only in a nonsubstantive way;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) FixPen (being a simple pull and push injection pen);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) YpsoMate device (two step, push-on-skin autoinjector);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) any user-controlled, disposable, variable dose pen product or component thereof which Lannett does not purchase from Ypsomed; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)any user-controlled, disposable variable dose pen product or component thereof which is not made for use with injectable insulin glargine and aspart respectively.

**Supply Agreement** shall mean the agreements (which may be amended from time to time) as set forth in clause D of the Preamble.

**Term** shall have the meaning set forth in Section 7(a).

**Territory** shall have the meaning as set forth in the Supply Agreement.

**UnoPen Device** shall mean the user-controlled, disposable, variable dose injection pen made and sold by Ypsomed serving as basis of the Lannett UnoPen Version.

------

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Timothy Crew, certify that:

1. I have reviewed this report on Form 10-Q of the Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in shareholders' equity and cash flows of the Company as of and for the periods presented in this report;

4. The Company's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting;

5. The Company's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

---

| |
|:---|
| Date: February 2, 2023 |
| /s/ Timothy Crew |
| Chief Executive Officer |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, John Kozlowski, certify that:

1. I have reviewed this report on Form 10-Q of the Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in shareholders' equity and cash flows of the Company as of and for the periods presented in this report;

4. The Company's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting;

5. The Company's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

---

| |
|:---|
| Date: February 2, 2023  |
| /s/ John Kozlowski |
| Vice President of Finance, Chief Financial Officer and Principal Accounting Officer |

---

------

## Ex-32

**Exhibit 32**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Lannett Company, Inc. (the "Company") on Form 10-Q for the quarter ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Timothy Crew, the Chief Executive Officer of the Company, and I, John Kozlowski, the Vice President of Finance, Chief Financial Officer and Principal Accounting Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp; The Report complies with the requirements of Section13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp; The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Dated: February 2, 2023 | /s/ Timothy Crew |
|  | Timothy Crew, |
|  | Chief Executive Officer |
| Dated: February 2, 2023 | /s/ John Kozlowski |
|  | John Kozlowski, |
|  | Vice President of Finance, Chief Financial Officer and Principal Accounting Officer |

---

------